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Abstract 
Abstract 
Objective: The objectives of this study were to determine if there is a significant effect on 
blood pressure, serum levels of magnesium and sports performance including 1RM and 10 
kilometre running time trial following Magnesium (Mg2+) supplementation over a five week 
intervention period in recreationally active athletes when compared to a 5 week placebo 
intervention.  
Methods: Subjects participated in a 14 week protocol which employed a randomized blind 
cross over controlled design. Fifteen subjects were initially screened and accepted for 
participation. During the protocol two subjects dropped out, failing to complete. This left nine 
male and four female subjects who were successful in completing the protocol (Age: 24.85 ± 
6.49 years, Height: 175cm ± 10.34 cm, Weight: 71.9 Kg ± 11.46 Kg). 
Results: Statistically significant differences were observed (P < 0.05) in the running time trial, 
blood pressure readings pre and post 10 kilometre running trial (systolic and diastolic) and in 
heart rate (HR) recorded at 10 minute intervals during the running trial following Mg2+ 
supplementation. Following the Mg2+ intervention there was an average decrease in 10K 
completion time of exactly 1 minute (1.77%) (P=0.001). A significant decrease in HR by 2.58 
BPM (2.58%) (P=0.03). Diastolic blood pressure was significantly reduced both pre and post 
completion of the 10 kilometre run by 10.23 mmHg (13.85%) (P=0.03) and 5.38 mmHg 
(7.38%) (P=0.008) respectively. Whilst a significant reduction in systolic blood pressure was 
only seen following the 10 kilometre run 8.23 mmHg (6.17%) (P=0.05).  
As Mg2+ is a co-factor in over 325 enzymatic reactions (Newhouse & Finstad, 2000), it‟s 
importance as a mineral is clear and warrants research to improve scientific knowledge into 
its role within health and sports performance, as Mg2+ deficiency can also be detrimental to 
health.  
Conclusion: The results of the current study show that 500mg/day of Mg2+ supplementation 
will significantly decrease time taken to complete a 10 kilometre run, reduce systolic and 
diastolic blood pressure and significantly reduce HR. 
 
Keywords: Magnesium (Mg2+); Blood Pressure; Hear Rate; Serum Magnesium.  
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Introduction  
Achieving optimal functioning and performance is highly sought after by many individuals. It 
is common knowledge in the current day that nutrition is a key factor in achieving this. An 
optimal diet must contain adequate amounts of macro and micro nutrients, aiming to fulfil the 
body‟s daily requirements (Gibney, Macdonald & Roche, 2003).  
 
Previous research into Magnesium (Mg2+) supplementations impact on sporting performance 
has been conflicting. Some studies have reported that Mg2+ may have a positive effect on 
sporting performance (Lukaski, Bolonchuk, Klevay, Milne & Sandstead, 1983; Brilla & Haley, 
1992; Brilla & Gunter, 1995) whilst conflicting literature suggests that Mg2+ supplementation 
will have no effect or a negative effect on performance (DeHann et al., 1985; Weight et al., 
1988; Ruddell et al.,1990; Terblanche et al., 1992; & Weller et al., 1998.). The goal of the 
current paper was to determine the effects of a 5 week 500mg Mg2+ supplementation 
intervention on subject‟s performance in a 10 kilometre run, bench press till fatigue trial, 
blood pressure and levels of Mg2+ found in blood serum compared to a placebo intervention 
period.   
Hypothesis    
Alternative Hypothesis: Mg2+ supplementation will significantly reduce time taken to complete 
a 10 kilometre running time trial.  
 
Null Hypothesis: Mg2+ supplementation will have no impact on time taken to complete 
running time trial.  
 
Literature Review  
Varying results have been reported around Mg2+ supplementation and the impact that it has 
on blood pressure, blood serum levels and athletic performance. This review will look to 
analyse the previous literature surrounding Mg2+ supplementation and its subsequent impact 
on blood pressure, blood serum levels and athletic performance.  
Magnesium within the body 
Mineral elements, such as magnesium (Mg2+), are required by the human body in modest 
amounts for the maintenance of health and the development of optimal functioning (Lukaski, 
1995). Mg2+ is an important mineral element and it is the fourth most abundant cation in 
living organisms resulting in Mg2+ being a cofactor to over 325 enzymatic reactions occurring 
within the body (Newhouse & Finstad, 2000). This suggests that deficiency of the mineral 
may have various physiological and exercise performance implications (Newhouse & 
Finstad, 2000; Wolf & Cittadini, 2003). 
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Elin (2010) stated that about 99% of total body Mg2+ is located in the bone, muscles and 
non-muscular soft tissue (table 1). Fifty to sixty percent of the stored Mg2+ is located in the 
bone, whilst the remaining is located in soft tissues and skeletal muscle (Aikawa, 1980). The 
Mg2+ content of the bones has been said to decrease with age, resulting in less 
bioavailability when the body‟s stores of Mg2+ are depleted (Maguire & Cowan, 2002). 
However, this will not prevent the bone from exchanging Mg2+ as a buffer when serum Mg2+ 
levels begin to deplete, as one third of skeletal Mg2+ may be exchanged to maintain 
physiological extracellular Mg2+ levels (Alfrey & Miller, 1973).   
Approximately 1% of the total body Mg2+ is present in the serum and intestinal bodily fluids 
(Elin, 1987). The mean serum Mg2+ concentration in humans is roughly 0.85 mmol/L, with a 
referenced interval of 0.7-1.mmol/L (Wacker, 1980). In serum, approximately one third of 
Mg2+ is bound to protein, 25% is bound to albumin and 8% to globulins (Kroll, 1985). For the 
two thirds of the plasma Mg2+ that is ultrafiltrable, approximately 80% is in the form of free 
ion and approximately 20% is complexed to phosphate, citrate and other compounds (Elin, 
1987). 
Table 1. Distribution of Mg
2+
 in the adult human being (Elin, R. J. 1988). 
 
Within serum and red blood cells Mg2+ is said to act as a counter ion for adenosine 
triphosphate (ATP) molecules (Jahnen-Dechent & Ketteler, 2012) Wherever there is ATP 
there is a need for Mg2+ in the biological process (Aikawa, 1980).   Protein synthesis requires 
the involvement of ribonucleic acid (RNA) and the genetic mechanism involving 
deoxyribonucleic acid (DNA) also have a need for Mg2+ (Aikawa, 1980). Cunningham, 
8 
Luke Pitkin: 09201403 
Rodríguez, & Messa (2012) also suggested that Mg2+ contributes to the regulation of heart 
rhythm, bone formation, vascular tone and platelet activated thrombosis. 
Mg2+ and calcium compete with one another for the same binding sites on plasma protein 
molecules (Walser, 1967; Hunter, Haworth & Southard 1976). It was reported that Mg2+ 
antagonises calcium dependant release of acetylcholine at motor endplates; this may 
suggest that Mg2+ is a natural calcium antagonist (Wacker, 1980). Calcium is seen as a 
powerful „death trigger‟ (Orrenius, Zhivotovsky, & Nicotera 2003). The role of Ca2+ as a death 
trigger was first suggested by Fleckenstein et al., (1977) who proposed that the influx of 
excess Ca2+ into the myocytes may be the mechanism underlying the cardiac pathology that 
occurs after ischemia. Later studies have emphasised the general importance of this 
observation, as both receptor overstimulation (Leonard, & Salpeter, 1979) and cytotoxic 
agents (Schanne, Kane, Young, & Farber 1979; Trump, & Berezesky, 1995) were found to 
cause an excessive influx of Ca2+ into cells (Orrenius, Zhivotovsky, & Nicotera 2003). 
Recommendations for the suggested daily intake of Mg2+ differ in the literature. Seelig (1964) 
concluded that at least 6 mg/kg per day were required for males and females to maintain an 
adequate balance of Mg2+. Furthermore in 1980, the food and nutrition board of the National 
Academy of Sciences and the National Research Council recommended a daily intake of 
300mg and 350mg for adult females and males respectively (National Academy of Sciences, 
1980). If you were to assume a mass of 70kg for males and 60kg for females this suggested 
intake would equate to 5 mg/kg per day. The Mg2+ intake for the average individual is very 
closely correlated with the total number of calories consumed (Flink, 1980), this is assuming 
that a large percentage of the calories are not derived from alcohol or refined sugars, which 
essentially have no mineral content. Nuts, green vegetables, soy beans, chocolate and 
whole grain cereals are foods all of which are rich in Mg2+ content (Elin, 1987). In addition to 
this drinking water, especially if it‟s “hard” water may be a major source of Mg2+. Mg2+ 
content is reduced during the water filtration process, resulting in “soft” water. This reduction 
in Mg2+ content may be a contributing factor in the increasing numbers of people suffering 
from hypomagnesemia in the population (Elin, 1987).  
To maintain an adequate Mg2+ status it is said that humans must consume Mg2+ at regular 
intervals (Jahnen-Dechent & Ketteler, 2012).  The daily allowance for Mg2+ is controversial 
as the literature is conflicting and varied, although values of ≥ 300 mg are usually reported 
with adjustment dosages for age, sex and nutritional status (Jahnen-Dechent & Ketteler, 
2012). The Committee On Medical Aspects (COMA) has calculated a RNI of 300mg/day for 
adult males and 270mg/day for adult females (COMA, 1991). The RNI for infants and 
children ranges from 55 to 280 mg/day. An RNI for Mg2+ during pregnancy was not 
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calculated by COMA. The suggested RNI for adult males and females is supported by other 
literature, which suggests a similar consumption of 350mg for males and 280-300mg for 
females respectively (Weast, 1987; Elin, 1988; Rude, 1996; Saris, Mervaala & Karppanen, 
2000). Mg2+ can also be acquired through drinking water, it is said that around 10% of daily 
Mg2+ intake will come from drinking water (Marx & Neutra, 1997). Chlorophyll is the main 
source of Mg2+ therefore suggesting that green vegetables would contain a high Mg2+ 
content. Furthermore, nuts, unprocessed cereals and seeds will also contain high levels of 
Mg2+ (Fox, Ramsoomair & Carter, 2001). Low Mg2+ levels are found in most available dairy 
products (Jahnen-Dechent & Ketteler, 2012). The literature suggests that when foods are 
processed a large percentage of Mg2+ is lost (Elin, 1988), this may be the cause of the 
decrease in consumption of Mg2+ seen in the Western society (Ford & Mokdad, 2003).    
It is suggested that Mg2+ actually inhibits calcium induced cell death (Reynolds, Joannides, 
Skepper, McNair, Schurgers, Proudfoot, & Shanahan 2004).  Apoptosis is a genetically 
controlled and evolutionary conserved form of cell death that is of importance for normal 
embryonic development and for maintenance of tissue homeostasis in the adult organism 
(Orrenius, Zhivotovsky, & Nicotera 2003). Apoptotic cell death is triggered by extrinsic 
receptor-mediated, or intrinsic mitochondria mediated signalling pathways that may induce 
death-associated proteolytic activities. Apoptosis occurs in an organised sequence of events 
(Kerr, Wyllie, & Currie, 1972). The cell primarily undergoes nuclear and cytoplasmic 
condensation with blebbing of the plasma membrane. It then breaks up into fragments, 
known as apoptotic bodies, which are recognised and engulfed rapidly by neighbouring cells 
or macrophages. The intracellular ATP concentration and the status of mitochondrial 
function are crucial factors that influence the mode of death (Eguchi, Shimizu, & Tsujimoto, 
1997; Leist, Single, Castoldi, Kühnle, & Nicotera, 1997). A link that has been made between 
Ca2+ and apoptosis was the finding that Ca2+ induced a typical apoptotic ladder-like DNA 
fragmentation pattern in isolated thymocyte nuclei through the activation of Ca2+ and Mg2+ 
dependant endonuclease (Wyllie, 1980; Cohen, & Duke1984). Subsequent dissection of the 
mechanism of glucocorticoid-induced apoptosis in thymocytes showed that extracellular Ca2+ 
was necessary for cell death to occur. For all these reasons it can be assumed that Mg2+ 
deficiency can result in poor health and living. 
When the human body is in a state of hypomagnesaemia it will aim to utilise some of the 
stores from the various organs and bones. There is said to be a considerable variation in the 
plasma/tissue exchange of Mg2+ in various organs (Maguire & Cowan, 2002). This 
observation indicates that each cell type will handle Mg2+ differently, again different to Ca2+ 
(Saris, Mervaala, Karppanen, Khawaja, & Lewenstam, 2000). Fat tissue, brain tissue, 
skeletal muscle, kidney parenchyma, myocardium, and lymphocytes all exchange 
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intracellular and extracellular Mg2+ at different rates. However, the equilibrium for Mg2+ 
among most tissue compartments is achieved at a much slower rate (Elin, 2010). It has been 
reported that Mg2+ exchanges extremely slowly or is non-exchangeable, furthermore one 
third of Mg2+ stored in the bones is transferrable with serum during a state of 
hypomagnesaemia (Jahnen-Dechent & Ketteler, 2012). Alfrey & Miller (1973) reported Mg2+ 
exchange to be varied with maximum bone uptake occurring within the first five minutes. 
Exchange of Mg2+ was virtually complete by four hours, with very little additional bone uptake 
occurring between 4 and 48 hours (Alfrey and Miller, 1973).  
Effects of high Mg2+ consumption 
High Mg2+ consumption through food has not been linked with any adverse health effects 
and has not been shown to pose any harm (Scientific Committee on Food, 2001). Mg2+ 
supplementation may be used by those failing to attain significant amounts through the diet 
and is considered to be safe. McDonald and Keen (1988) have claimed that excessive Mg2+ 
consumption will not cause any serious issues, although Al-Ghamdi et al (1994) showed that 
anything over 500 mg/day of Mg2+ supplementation may cause gastrointestinal difficulties.  
Mg2+ absorption and excretion  
Mg2+ homeostasis is maintained by the intestine, kidneys and bones (Jahnen-Dechent & 
Ketteler, 2012). Mg2+ is absorbed in the intestine and stored in the bone. Any excess Mg2+ 
that has been consumed will be excreted by the kidneys, then removed from the body in 
urine. Absorption of Mg2+ mainly takes place in the small intestine (Graham, Caesar & 
Burgen, 1960; Fox, 2001; Touyz, 2004), although Mg2+ is also absorbed in the large 
intestine. Both the duodenum and jejunum have a high fractional absorption of Mg2+. These 
segments of intestine are relatively short however, and the transit time is rapid. Therefore 
their relative contribution to total Mg2+ absorption is less than that of the ileum. Two Mg2+ 
absorbing pathways have been identified in the mammalian intestine. Para-cellular transport 
is a passive mechanism which involves absorbing Mg2+ through small spaces between the 
epithelial cells. The second system involves the active transport of Mg2+ to the blood via the 
interior of the epithelial cell. During transport Mg2+ must pass through two cell membranes 
(Baaij, Hoenderop & Bindels 2012). Para cellular Mg2+ absorption is responsible for roughly 
80-90% of intestinal Mg2+ uptake.  
It has been suggested that the ileum and distal parts of the jejunum are known to be the 
most permeable for ions because of the relatively low expression of tightening claudins 1, 3, 
4, 5 and 8 (Amasheh,  Fromm, & Günzel, 2011). As such paracellular Mg2+ transport seems 
mainly restricted to these areas. Claudins 16 and 19, linked with Mg2+ permeability (Hou, et 
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al., 2009), are not expressed in the small intestine (Amasheh, Fromm & Gunzel, 2011). 
Therefore, the exact mechanism involved in the facilitation of Mg2+ absorption remains 
unknown.  
The average dietary intake of Mg2+ is roughly 300 mg/day, all derived primarily from green 
vegetables, cereal grains and meat. An individual consuming this diet absorbs around 40% 
of the Mg2+ consumed, most of which is absorbed primarily in the small intestine (Elin, 1987). 
The absorption process is said to commence roughly 1 hour after consumption and 
continues at a uniform rate for 2-8 hours.  After 12 hours of ingestion the material will 
normally be in the large bowel, which absorbs very little Mg2+. The absorption of Mg2+ in the 
small intestine is inversely related to consumption levels. When a diet low in Mg2+ is 
consumed up to 75% of that ingested Mg2+ may be absorbed, whilst when consuming a diet 
rich in Mg2+ as little as 25% may be absorbed (Elin, 1987).   
The major excretory pathway for absorbed Mg2+ is via the kidneys (Elin, 1987). The renal 
excretion of Mg2+ is said to lie between 120 to 140 mg/24 h, for a person consuming a diet 
adequate in Mg2+ (Wacker, 1980; Aikawa, 1981). Therefore, the amount of Mg2+ that is 
absorbed in the small intestine is similar to the amounts excreted by the kidneys.  This 
process allows one to maintain Mg2+ balance (Elin, 1987). The kidney is also the major 
organ that is involved in the concentrations of Mg2+ in the serum. The excretion rate of Mg2+ 
from the kidney can range from 10 to 500 mg/24 hour, depending on the Mg2+ levels in the 
plasma.  
It has been estimated that 70% to 80% of the plasma Mg2+ is filtered through the glomerular 
membrane; in a person consuming an adequate diet, the Mg2+ which is bound to the protein 
does not pass through the glomerular membrane (Elin, 1987). Roughly 20% to 30% of the 
filtered Mg2+ is absorbed along the proximal tubule (Quamme, 1986). The primary site for the 
absorption of Mg2+ is the thick ascending limb of the loop of Henle, where more than 50% of 
the filtered Mg2+ is reabsorbed (Quamme, 1986). The distal tubules and collecting ducts 
therefore absorb next to no Mg2+.   
The excretion of Mg2+ follows a circadian rhythm, with most Mg2+ being excreted in the 
evening/night (Fox, Ramsoomair, & Carter, 2001). Under normal physiological conditions 
approximately 2400mg of Mg2+ located in blood plasma is filtered by the glomeruli in 24 
hours. Of this filtered Mg2+, 95% is re-absorbed instantaneously, leaving 3-5% which is 
excreted in urine (Massry & Seelig, 1977; Saris, Mervaala & Karppanen, 2000). However, 
the kidneys can manipulate the Mg2+ excretion by increasing or lowering the amount 
removed from the serum. It is believed that the excretion and reabsorption rates can 
fluctuate immensely from 0.5% to 70% respectively. This means that the kidneys are able to 
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conserve Mg2+ when the body is falling into a state of hypomagnesemia; by reducing the 
excretion amount in urine.  On the other hand, the kidneys can also increase excretion when 
the body is in a state of hypermagnesemia (Jahnen-Dechent & Ketteler, 2012). 
Assessing Mg2+ status  
Assessing Mg2+ within the body is a complex task; the most common method of assessing 
Mg2+ status is via evaluation of serum Mg2+ concentrations (Huijgen, Sanders & Van Olden, 
1998; Touyz, 2004). Although serum Mg2+ concentration is not comparable with Mg2+ stored 
within tissues, therefore, it is not an accurate account of overall body Mg2+ (Elin, 2010; 
Spiegel, 2011). Fawcett, Haxby & Male (1999) reported that only 1% of bodily Mg2+ is 
located in extracellular fluids, furthermore only 0.3% of bodily Mg2+ was found in the serum, 
where it is present in three altered states, ionised (62%), protein bound (33%) and 
phosphate (5%) with most Mg2+ being stored in bone (53%), intracellular compartments of 
muscle (27%) and soft tissues (19%). Fawcett, Haxby & Male (1999) concluded therefore, 
that serum Mg2+ is a poor indicator of Mg2+ status and can only be used as a predictor or an 
indicator of Mg2+, not total body Mg2+ content. Red blood cell and muscle Mg2+ 
concentrations have also been reviewed, although the relationship between these and total 
body Mg2+ is still unresolved (Fawcett, Haxby & Male 1999). 
A second approach to assess Mg2+ status is via urinary Mg2+ excretion. Duley & Johanson 
(1994) suggested an estimation of normal renal Mg2+ in 24 hours. This estimated 24 hour 
renal excretion was a urinary loss of 3.6 mmol for females and 4.8 mmol for males. A further 
refinement is the Retention of Mg2+ Test. After an initial 24 hour baseline urine sample is 
attained, a Mg2+ load is provided to the patient. Following supplementation another urine 
sample is collected 24 hours later, if excretion of Mg2+ is 60-70% or greater this would 
suggest that Mg2+ depletion is unlikely. This test aims to quantify the exchangeable pool of 
Mg2+ which is commonly located in bone (Ryan, 1991). This approach to assessing Mg2+ 
status will not be adopted in the current trial due to the added time commitment it will place 
on the subjects.  
Hypomagnesemia 
As accurate clinical tests of Mg2+ status are still lacking, it is hard to diagnose Mg2+ 
deficiency (Jahnen-Dechent & Ketteler, 2012). Evaluation of serum Mg2+ concentration and 
collection of urine samples are the most accurate assessments available at this present 
time, for the diagnosis of Mg2+ deficiency. Following this a Mg2+ retention test could also be 
performed (Elin, 1988). Previous literature has concluded serum urine of ≤ 0.75 mmol/L as 
deficient in Mg2+ (Chernow, Bamberger & Stoiko, 1983; Whang & Ryder, 1990; Mori, 1990).  
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Mg2+ deficiency is highly common in hospitalised patients with a prevalence of 65%. This 
figure has been reported to increase in intensive care units (Rude, 1993). Prolonged Mg2+ 
deficiency may result in poor health conditions such as cirrhosis, cerebrovascular disease 
and malignant tumours (Chernow, Bamberger & Stoiko, 1989). Mg2+ also plays a role in 
muscle contraction. This suggests that Mg2+ deficiency may lead to muscle cramping, 
ultimately resulting in a reduction of muscle performance (Touyz, 2003).  
 
Bergeron (2003) claims that deficiency in a variety of minerals, mainly Mg2+, calcium and 
potassium can cause muscle cramps during exercise (Benda, 1989; Williamson, Johnson, 
Hudkins & Strate, 1993). Any athlete competing in excessive temperature conditions may 
subsequently become deficient in one or more of the discussed minerals could certainly 
experience muscle cramps or various other neuromotor issues (Bergeron, 2003). This may 
suggest that calcium; Mg2+ and potassium supplementation may be warranted to aid 
prevention of muscular cramping. Alongside deficiency in essential minerals insufficient 
conditioning and fatigue may contribute to muscle cramping in an over worked muscle 
(Bentley, 1996; Schwellnus, Derman & Noakes, 1997). This cramping is often localised and 
can be resolved relatively quickly by stretching, massaging or icing. With heat cramps the 
affected areas become more widespread across many voluntary muscles, this usually 
inhibits performance.  Stretching, massaging and icing are interventions that can be used to 
reduce heat cramps making them much less persistent (Bergeron, 2003).  
 
As an individual becomes progressively dehydrated the extracellular fluid compartment 
becomes increasingly contracted (Nadel, Mack & Nose, 1993). A loss of interstitial fluid may 
result in a deformation of the nerve endings thus increasing the surrounding ionic and 
neurotransmitter concentrations (Bergeron, 2003). This can cause selected motor nerve 
terminals to become hyperexcitable and spontaneously begin to discharge (Jansen, Joosten 
& Vingerhoets, 1990; Layzer, 1994). An athlete‟s first indication of heat cramps usually 
begins with twitches in the voluntary muscles that are almost undetectable. These twitches 
are often more evident when an athlete is stationary, for example when a tennis player is 
sitting down during change over. If an athlete can identify the early twitching stages and deal 
with them according, a full blown heat cramp which would occur 20-30 minutes following the 
initial onset can be prevented (Bergeron, 2003).  
 
The onset of Mg2+ deficiency can be initiated in many different ways. The most common 
onset is by reduced intake, usually caused by poor nutrition, resulting in decreased 
absorption (see figure 1). Deficiency may also be triggered by increased excretion of Mg2+ in 
some medical conditions such as diabetes mellitus (Jahnen-Dechent & Ketteler, 2012). 
14 
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Chronic Mg2+ deficiency is hard to diagnose this is because an individual may carry a 
sufficient level of Mg2+ in the serum, whilst this may have been sourced from Mg2+ stores 
located in the bone, ultimately depleting those stores resulting in total body Mg2+ depletion. It 
is near impossible to assess which tissue pools of the body are in equilibrium for Mg2+. If the 
level of Mg2+ in the serum is attained, it may not provide any further information about the 
concentration of Mg2+ in other bodily tissues (Elin, 1987). 
 
Three separate studies have shown no correlation amongst serum, erythrocyte and 
mononuclear blood cell (MBC) concentrations of Mg2+ in humans (Elin, 1982; Elin, 1985; 
Millart, 1985). Therefore, data on Mg2+ concentration for a particular tissue will be limited to 
that tissue. Serum is undoubtedly the most frequently used tissue for determining Mg2+ 
status (Arnaud, 2008). However, the concentration of Mg2+ in serum has not been shown to 
correlate with any other tissue pools of Mg2+ except from interstitial fluid. For assessing 
acute changes in Mg2+ status the assessment of the Mg2+ concentration found in the serum 
is valid. This investigation will aim to assess Mg2+ status by using the serum attained during 
collecting venepuncture samples.  
 
Some literature suggests that healthy individuals will have a Mg2+ serum concentration that 
is closely maintained within the physiological range (Walser, 1967; Rude, 1996; Fox, 
Ramsoomair & Carter 2001). This referenced range is 0.65-1.05 mmol/L for total Mg2+ 
concentrations in adult blood serum (Tietz, 1990) and 0.55-0.75 mmol/L for ionised Mg2+ 
(Maj-Zurawska, 1994). Arnaud, (2008) reported, serum Mg2+ levels <0.75 mmol/L as a useful 
measurement for deficiency. Different populations and methodologies for the determination 
of Mg2+ probably contribute to the width of this range (Wacker, 1980). This range will be 
used in this investigation and blood serum levels below 0.75 mmol/L will be classified as 
deficient.  
 
Chronic Mg2+ deficiency has also been linked to hypertension, malignant tumours, kidney 
stones, and atherosclerosis.  
 
Hypermagnesemia 
 
As previously discussed the kidneys play a vital role in the regulation of Mg2+ status within 
the body. In a state of chronic kidney disease the compensatory mechanisms may be 
affected, resulting in the development of hypermagnesemia (Cunningham, Rodriguez, & 
Messa 2012). Hypermagnesemia may also develop with excessive consumption of oral Mg2+ 
or drugs containing Mg2+ such as laxatives (Xing & Soffer, 2001). Prevalence rates of 
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hypermagnesemia are much lower than hypomagnesemia with only 9.3% of hospitalised 
individuals suffering with hypermagnesemia (Wong, Rude & Singer, 1983). These reported 
figures are disputed as Hashizume & Mori, (1990) reported a prevalence of only 7.9% within 
hospitalised individuals and Whang & Whang, (1990) reported an even lower prevalence of 
only 5.7% in hospitalised individuals. In intensive care the prevalence of hypermagnesemia 
increased, with reports indicating a prevalence rate of 13.5% (Escuela, Guerra & Anon, 
2005).  
 
Signs of hypomagnesemia and hypermagnesemia 
 
Clinical signs and symptoms of hypomagnesemia and hypermagnesemia are highly similar 
and often not specific. Signs of hypomagnesemia may include symptoms such as; muscle 
fasciculation, tremor, agitation, depression and hypokalaemia (Wacker, 1980; Hashizume & 
Mori, 1990; Saris et al., 2000). In the early stages of hypomagnesemia an individual may feel 
an overall sense of weakness alongside vomiting and tremors (Hashizume & Mori, 1990). If 
hypomagnesemia is prolonged then the symptoms will become worse. Examples of the 
symptoms include; muscle cramps, sudden changes in behaviour caused by excessive 
electrical activity, numbness, tingling and personality changes (Hashizume & Mori, 1990). In 
extreme cases of hypomagnesemia an individual may experience heart irregularities.   
 
Hypermagnesemia may stay undetected for a long time; this is due to the lack of clinical 
symptoms and no drop in the serum concentrations due to the body‟s ability to maintain 
homeostasis by the quantitative influx and efflux of Mg2+ across intestine, bone and kidney. 
(Hashizume & Mori, 1990). If Mg2+ intake reaches an extreme an individual may suffer 
neuromuscular dysfunction, this can vary from drowsiness to respiratory depression.  
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Fig. 1. A schematic overview of Mg2+ absorption pathways in the intestine, showing proteins 
associated with Mg
2+
 transport in enterocytes. In the intestinal epithelia, paracellular Mg
2+
 
transport occurs via unidentified claudins, occurring concurrently with transcellular Mg
2+
 
transport via transient receptor potential channel melastatin member 6 (TRPM6) and TRPM7 to 
facilitate Mg
2+
 absorption. (Baaij, Hoenderop & Renė 2012).  
 
In otherwise healthy individuals, Mg2+ supplementation is usually successful in treating 
individuals suffering mild hypomagnesemia (Guerrero-Romero et al., 2004). Fuentes, 
Salmon & Silver (2006); Mathers & Beckstrand (2009) have reported that both acute and 
chronic Mg2+ supplementation is tolerated and safe for individuals suffering from 
hypomagnesemia.  Discontinuation of Mg2+ supplementation is suggested for treating mild 
cases of hypermagnesemia. In extreme cases of hypermagnesemia haemodialysis may be 
required.  
 
Too much Mg2+ consumed in the diet through food ingestion does not pose a health risk in 
healthy individuals because the kidneys are able to eliminate excess amounts via urine 
(Muso, 2009). However, high doses of Mg2+ from dietary supplements or medication can 
often result in diarrhoea that may be accompanied by abdominal cramping (Ross et al., 
2011). Forms of Mg2+ most commonly reported to induce laxative effects include Mg2+ 
sulphate carbonate, chloride gluconate and oxide (Ranade & Somberg, 2001). The laxative 
effects of Mg2+ salts are reportedly due to osmotic activity of unabsorbed salts in the 
intestine and colon and the simulation of gastric motility.  
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Extreme dosages of Mg2+ containing laxatives and antacids typically provided more than 
5,000 mg/day of Mg2+ and have been associated with Mg2+ toxicity (Kutsal et al., 2007), 
including fatal hypermagnesemia in a 28 month old boy (McGuire, Kulkarni & Baden, 2000) 
and elderly man (Onishi & Yoshino 2006). Symptoms of Mg2+ toxicity usually start to develop 
after serum concentrations reach an excess of 1.74 – 2.61 mmol/L. common symptoms can 
include hypotension, nausea, vomiting, facial flushing, retention of urine, depression and 
lethargy before progressing to muscle weakness, breathing difficulties, irregular heartbeat 
and cardiac arrest (Musso, 2009). The risk of Mg2+ toxicity increases with impaired renal 
functioning or kidney failure because the ability to remove excess Mg2+ is reduced or 
completely lost (Musso, 2009).  
 
Previous literature has reported that ingestion of Mg2+ may affect the body in different ways 
encouraging different responses. One of the most commonly researched effects of Mg2+ 
ingestion is the possibility of a reduction in blood pressure (Jee, et al., 2002). A reduction in 
blood pressure can be a highly beneficial adaptation for the body as the vasodilation effect 
may help to improve performance in cardiovascular activities and improve the health of the 
population suffering from hypertension.  
 
Blood pressure 
Blood pressure (BP) is a measure of the pressure that is exerted by the blood against the 
wall of the vessels, most commonly the arteries. During one cardiac cycle the blood pressure 
will vary between a maximum (systolic) and a minimum (diastolic). The systolic and diastolic 
blood pressures will both be caused by the contraction and relaxation of the heart; during 
each cardiac cycle (Caro, Pedley, Schroter, & Seed; 1978). The systolic blood pressure in 
normotensive individuals has been said to average around 120 mm Hg during the systole 
phase of the cardiac rhythm. During the hearts relaxation phase (diastole) the blood 
pressure will lower, producing the diastolic blood pressure reading. The diastolic blood 
pressure in normotensive individuals has been said to average at around 60 - 80 mmHg. 
 
For over three decades the National Heart, Lung, and Blood Institute (NHLBI) has 
administered the National High Blood Education Programme (NHBPEP) coordinating 
committee (Chobanian, Bakris, Black, Cushman, Green, Izzo & Roccella 2003). The 
committee consists of a coalition of 39 major professional, public and voluntary 
organisations. One important function of the committee is to issue guidelines and advisories 
to increase awareness, prevention, treatment and control of hypertension (Chobanian, 
Bakris, Black, Cushman, Green, Izzo & Roccella 2003). 
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The guidelines which can be seen in Table 2 provide the classification of blood pressure for 
adults aged 18 years and older. The classification should be based on the average of two or 
more properly measured, seated blood pressure readings on each or at least two visits. 
These classification guidelines were attained from the European Society of Hypertension 
and are the classification guidelines referred to in the United Kingdom.  
 
Table 2. Definitions and classification of blood pressure for adults (European Society of Hypertension, 
2013).  
 
 
 
Pesola, Pesola, Lin, Nelson, & Westfal (2000) conducted a study, which supports the 
normotensive blood pressure values of 120mmHg over 80mmHg. The trial recorded bilateral 
indirect blood pressures from 100 subjects with no history of hypertension. All blood 
pressures were taken in a seated position by two observers, one of which recorded the 
systolic and diastolic blood pressures announced by the fellow observer that was taking the 
blood pressure, blinded to the values. This blinding measure would have prevented the 
observer taking the blood pressure, from subconsciously recording falsified results. 
Therefore this increases the validity of results collected in the trial.  
 
The obtained results for average left and right systolic blood pressures were 112.1mmHg ± 
16.5 and 112.7mmHg ± 16.3, whilst the average left and right diastolic pressures were 
64.4mmHg ± 11.6 and 63.5mmHg ± 9.9. Statistical analysis reported that there was no 
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significant difference in systolic or diastolic blood pressures between different genders of 
subjects with right or left hand dominance (Pesola et al., 2000). Results of this study support 
the normotensive values presented by the joint national committee on prevention, detection, 
evaluation and treatment of high blood pressure which are illustrated in table 2.  However, 
this does not present an average blood pressure reading as each individual will be different 
and there are several determinants such as height, weight and age that can influence blood 
pressure at any given moment.  
 
Historically diastolic blood pressure was seen as the most importation pressure in predicting 
coronary heart disease (Mancia, Rosei, Cifkova, DeBacker, Erdine, Fagard, & Zannad., 
2003). This is present in the design of major randomised control studies that were conducted 
in the 1990‟s (Collins, Peto, MacMahon, Godwin, Qizilbash, Hebert & Fiebach., 1990). 
However, since the 1990‟s there has been confirmation via controlled trials that both systolic 
and diastolic blood pressures are related with cardiovascular disease (Vasan, Larson, Leip, 
Evans, O'Donnell, Kannel, & Levy, 2001). 
 
Hypertension 
Hypertension has been reported as being a major risk factor in inducing cardiovascular 
disease (CVD). Examples of various types of CVD are strokes, ischemic heart disease, 
cardiac failure and end stage renal disease (Touyz, 2003). Hypertension is an abnormal 
alteration in the stiffness of blood vessel (arterial) walls within the body. Major vascular 
changes associated with hypertension include reduced vessel lumen diameter and media 
thickening which may be due to an increase in peripheral resistance (hardening of the 
arteries) ultimately impairing the body‟s vasodilatation ability (Touyz et al., 2003). Mg2+ has 
been reported to have a positive effect on reducing peripheral resistance allowing 
vasodilatation to occur within the arteries. 
 
Hypertension is caused predominantly by a haemodynamic abnormality which involves a 
reduction in the size of the lumen in the arteries of the human body this is commonly known 
as peripheral resistance. As the lumen in the arteries begins to shrink the resistance in the 
artery begins to increase, resulting in an overall increase in hypertension. 
The onset of hypertension may also be related to functional, structural and mechanical 
alterations in the body (Korner et al., 1989; Folkow, 1990). It is reported that 43 million 
people the United States are currently suffering with hypertension and are taking 
antihypertensive medications. Essential hypertension accounts for around 95% of 
hypertension cases (Carretero & Oparil., 2000) and it is a worldwide complication accounting 
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for 6% of adult deaths (Burt, Whelton, Roccella, Brown, Cutler, Higgins, Horan & Labarth.; 
1995). 
 
Diseases of the heart and circulatory system (cardiovascular disease or CVD) occurring due 
to hypertension are the main cause of deaths in the United Kingdom and accounted for 
almost 180,000 deaths in 2010. The most common forms of CVD are coronary heart disease 
and stroke. Around 45% of all CVD deaths are from coronary heart disease and over a 
quarter, roughly 28% are a result of strokes (British Heart Foundation, 2012). 
 
Coronary heart disease alone is the most common cause of death in the United Kingdom. In 
2010, just under one in five male deaths and one in ten female deaths were from the 
disease, this is approximately a grand total of 80,000 deaths in one year (British Heart 
Foundation, 2012). Strokes caused a total of 50,000 deaths whilst another 49,000 deaths 
occurred from various other circulatory diseases. Acute myocardial infarction (heart attack) is 
also another significant cause of death in the United Kingdom, with the majority of deaths 
occurring in individuals over the age of 85 (British Heart Foundation 2012).   
 
The exact form of the underlying genetic mechanism of hypertension still remains unclear. 
The identification of variant genes that contribute to the development of hypertension is 
complicated by the fact that the two entities that determine BP (Cardiac output and total 
peripheral resistance) are controlled by other intermediary phenotypes, including the 
autonomic nervous system, vasopressor/vasodepresser hormones, the structure of the 
cardiovascular system, body fluid volume renal function and many others (Gong & Hubner, 
2006). Identification of genes underlying BP variation has the capacity to define primary 
physiological mechanisms causing this trait, thereby clarifying disease pathogenesis, 
establishing molecular diagnostics and developing a novel therapy (Lifton, Gharavi & Geller; 
2001). Over the last decade progress has been made towards the detection of genes 
underpinning several Mendelian forms of hypertension traits, which may present early in life 
with distinct phenotypes (Lifton, Gharavi & Geller; 2001). Some variables which may lead to 
an increase in blood pressure, resulting in hypertension are: weight, age, gender, sedentary 
lifestyle, high alcohol consumption, high salt intake, low calcium intake and low potassium 
intake (Sever & Poulter., 1989; INTERSALT Co-operative Research Group., 1988). 
   
Lewington et al (2002) supported the theory that there is a linear relationship between blood 
pressure and CVD. Lewington, conducted a meta-analysis which concluded that between 
the ages of 40-69 there is an increase in mortality rates from ischemic heart disease. The 
findings suggested that with each increase in systolic blood pressure of 20mmHg and in 
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diastolic blood pressure of 10mmHg there would be a twofold increase in the risk of stroke 
mortality. These findings help to link the increase seen in blood pressure with the 
subsequent increase in mortality rates. 
 
Mg2+ effect on blood pressure 
Several studies have demonstrated that Mg2+ supplementation will have a positive effect in 
reducing blood pressure in both hypotensive and normotensive individuals (Dyckner& 
Wester,1983; Motoyama et al, 1989; Witterman et al, 1994; Kazue et al, 1997; Kawano, 
1998 & Doyle, 1999.) whilst the results of several studies also contrast these finding 
suggesting that Mg2+ supplementation will fail to aid in the reduction of blood pressure 
(Cappuccio et al, 1985; Henderson et al, 1986; Sacks et al, 1995; Yamamote et al, 1995 & 
Sacks et al, 1998). 
Mg2+ has been linked to various physiological functions occurring within the human body, 
including cardiovascular regulation as it may play an important role in the control of neural 
activities, cardiac excitability, neuromuscular transmission, muscular contraction, vascular 
tone, blood pressure and peripheral blood flow (Altura, 1995). Therefore, it may be assumed 
that deficiency of this micronutrient may result in abnormalities occurring such as heart 
disease, congestive heart failure, diabetes, insulin resistance and as discussed previously 
high blood pressure resulting in hypertension (Altura, 1995). 
Increased concentrations of extracellular Mg2+ cause vasodilation, whereas decreased 
concentrations cause contraction and potentiate agonist evoked vasoconstriction. The exact 
cellular basis for the molecular contractile action of Mg2+ is unknown, but it has been 
suggested that Mg2+  influences Ca2+ which has been shown to increase contractility of 
vascular smooth muscle cells (Jahnen-Dechent & Kettele, 2012). Inside the vascular smooth 
muscle cells, Mg2+ acts by inhibiting transmembrane calcium transport and calcium entry into 
the cell thus decreasing contractile actions of vasoactive agents acting as a calcium 
antagonist thereby modulating the vasoconstrictor actions of increased Ca2+ in smooth 
muscle cells. This can be seen in figure 2 which displays the role which Mg2+ plays in 
reducing smooth muscle cell contractility. Elevated levels of Mg2+ compete with the influx of 
Ca2+ and stimulate a mediated calcium efflux resulting in decreased intracellular free calcium 
which in turn may reduce vascular contractility reducing blood pressure by vasodilatation 
(Touyz, 2003) 
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Fig. 2. Displays the mechanism of action by which intracellular Mg2+ can reduce the levels of 
Ca
2+
 to aid a reduction in blood pressure (Touyz et al, 2003).  
Kawano (1998) conducted a study looking into the effects of Mg2+ supplementation in 
hypertensive patients. This study was of a double blind randomised cross over design 
involving 62 subjects of both genders between the ages of 35-74y with baseline blood 
pressure levels of > 140mmHg (systolic) and > 90mmHg (diastolic). The protocol involved a 
randomised crossover design where subjects were supplemented with either 8 weeks of 
Mg2+ followed by an 8 week control period or an 8 week control period followed by an 8 week 
Mg2+ period. Twenty mmol/day (480mg) of Mg2+ supplement was given to the subjects for 
ingestion. Blood pressure measurements were recorded in the home environment twice a 
day throughout the duration of the intervention period and the control period, whilst casual 
office (work environment) and 24 hour ambulatory blood pressures were measured at the 
end of the control period and at the end of the intervention period.  
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Table 3. Office, Home and 24-hour ambulatory BP during control supplementation and Mg
2+
 
supplementation periods (Kawano et al., 1998). 
 
Table 3 displays the findings that were recorded by Kawano (1998), clearly showing a 
reduction of blood pressure in the office of 3.7±1.3 (systolic) and 1.7±0.7 (diastolic), a blood 
pressure reduction in the home of 2.0±0.8 (systolic) and 1.4±0.6 (diastolic) and a reduction 
in the 24 hour assessment of 2.5±1.1 (systolic) and 1.5±0.7 (diastolic) in the day and 2.5±1.1 
(systolic) and 1.2±0.7 (diastolic) in the night. 
The resulting drop in blood pressure was concluded to be significantly different in the office, 
at home and in the 24 hour readings in male populations. Female populations also recorded 
a lower blood pressure post intervention in the office, at home and 24 hour trails, although 
these findings were not concluded as having a significant difference to baseline recordings. 
These findings may be evidence of how blood pressure can be reduced successfully in the 
male population by Mg2+ supplementation although this cannot be concluded for both 
genders as female‟s reductions were not significantly different. 
As well as reporting lower blood pressure readings when comparing males to females 
Kawano (1998) also reported that Mg2+ supplementation tended to have a greater effect on 
the older populations when compared with the younger populations. Gender, age, height, 
and weight all are determining factors in hypertension. Kawano (1998) suggested that there 
could be several mechanisms responsible for the significant decrease in blood pressure. 
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Mg2+ ions lower resting levels of intracellular Ca2+ by competing with Ca2+ for binding sites 
and modulating Ca2+ binding and release from the sarcoplasmic reticulum thus inducing 
vasodilation as an intracellular Ca2+ blocker (Kawano, 1998). At the cell membrane, Mg2+ 
regulates ion flux through voltage-gated, acetylcholine-activated, Ca2+-activated, and ATP-
activated K+ channels. These action may also be involved in the cardiovascular effects of 
Mg2+ (Kawano, 1998). 
Doyle et al, (1999) presented academic research also suggesting that Mg2+ has an important 
role in the regulation of blood pressure. Doyle (1999) also highlighted that Mg2+ 
supplementation may have a beneficial role in bone growth and metabolism. Doyle (1999) 
conducted a double blind placebo controlled, randomised crossover epidemiological study, 
involving 26 young and healthy females with an average age of 23± 2, height of 1.64m ± 
0.05, weight of 60.3kg ±7.6 and a body mass index (BMI) of 22.2 ± 2.  
The testing consisted of two different periods each lasting for a duration of 28 days, during 
which Mg2+ supplementation was given to the subjects, the Mg2+ intakes were 11.3mmol or 
21.6mmol of Mg2+ per day. Subjects were assigned to one of the Mg2+ interventions or the 
placebo intervention for a period of 28 days after which a cross-over occurred. Doyle (1999) 
found no significant difference in systolic or diastolic blood pressures for either 
supplementation groups, conflicting the findings of Kawano (1998). These findings contradict 
the theory that Mg2+ supplementation may reduce blood pressure, although these findings 
may have been due to the short duration of the intervention. Subjects were only asked to 
consume Mg2+ supplementation for a period of 28 days which may be a contributing factor 
as to why blood pressure was not seen to fall significantly.  
Although there are many different studies reporting a reduction in blood pressure with Mg2+ 
supplementation it cannot be concluded that supplementation will have the same effect if 
administered to a subject already attaining the recommended daily allowance of Mg2+ in their 
diet as many studies have failed to assess the dietary intake of subjects. This provides a 
rationale for this research as the methodology proposed aims to assess the dietary intakes 
of subjects partaking in the testing procedure and analyse if Mg2+ supplementation will have 
a significant effect on performance, blood pressure and serum levels when RNI of Mg2+ is 
already acquired through the diet.  
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Effect of exercise on blood pressure 
Alongside Mg2+ supplementation exercise has also been reported to have an effect on blood 
pressure. Exercise is commonly known to have favourable effects on blood pressure, within 
individuals (Fagard, 2006). This would support the theory that fitter individuals will have 
lower systolic and diastolic resting blood pressure readings 
Fagard (2006) stated that exercise can be divided into two broad categories dynamic, 
aerobic endurance training and resistance training.  Aerobic endurance training is generally 
conducted to increase aerobic stamina; this type of exercise usually involves recruiting large 
muscle groups in an aerobically active manner.  
Cornelissen and Fagard (2005) performed a comprehensive meta-analysis to assess the 
effect that exercise will have on blood pressure. The meta analysis involved a total of 72 
trails, consisting of 105 study groups, n=3936. Cornelissen and Fagard (2005) concluded 
that aerobic exercise will have a positive effect on reducing blood pressure in both 
normotensive and hypertensive individuals and their findings are displayed below in Table 4. 
It was also concluded that lowering of blood pressure as a result of exercise will be greater 
in hypertensive individuals rather than normotensive individuals (Cornelissen & Fagard, 
2005). 
 
Table 4. Baseline data for all groups and weighted net changes in response to aerobic endurance 
training (Cornelissen & Fagard, 2005). 
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These results may indicate that aerobic endurance training can have a positive effect in the 
reduction of blood pressure. This may be due to a reduction in systemic vascular resistance, 
in which the sympathetic nervous system and the renin-angiotensin system appear to be 
involved (Fagard, 2006).  
The second category of exercise described was resistance training, which refers to exercise 
involving strength, weight, static or isometric exercises incorporated specifically to 
encourage an increase in muscular strength, endurance and power (Fagard, 2006). It has 
been suggested that resistance exercise will also reduce blood pressure by reducing the 
peripheral resistance at rest (Kelley & Kelley, 2000). 
Kelley & Kelley, (2000) conducted a meta-analysis aiming to examine the effect that 
resistance exercise will have on blood pressure. The analysis conducted involved 11 
studies, containing a total of 320 subjects. The overall result of the meta-analysis suggested 
that progressive resistance exercise results in small reductions in resting, systolic and 
diastolic blood pressures concluding that progressive resistance exercise will be effective in 
reducing resting systolic and diastolic blood pressures in adults.   
Mg2+‟s effect on sports performance   
It has also been shown that Mg2+ may have an effect on athletic ability and performance. 
Some studies have reported that Mg2+ may have a positive effect on sporting performance 
(Lukaski, Bolonchuk, Klevay, Milne & Sandstead, 1983; Brilla & Haley, 1992; Brilla & Gunter, 
1995) whilst conflicting literature suggests that Mg2+ supplementation will have no effect or a 
negative effect on performance (DeHann et al., 1985; Weight et al., 1988; Ruddell et 
al.,1990; Terblanche et al., 1992; & Weller et al., 1998.) 
Mg2+ has been deemed essential in during a wide variety of cellular activities and is 
necessary for maintaining optimal muscle performance and muscle contraction (Dominguez 
et al., 1992). Mg2+ has been shown to significantly increase muscle strength in young 
subjects (Brilla & Haley, 1992).  Rodrigues et al (2003) stated that studying the performance 
for different intensities (5 of 1RM) may help understand the behaviour of different muscle 
groups and different fitness levels.  
Brilla and Gunter (1995) conducted a double blind four week cross-over design study on 20 
females and 12 males (recreationally active). After consumption of either placebo or Mg2+ 
supplementation (314mg/day), subjects completed an exercise trial which involved 
performing contractions on an isometric leg dynamometer until exhaustion. After another 
four weeks supplementation subjects returned for a second isometric leg trial to exhaustion. 
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They reported that there was a significant increase in time to fatigue when Mg2+ was 
compared to placebo. This may suggest that Mg2+ is effective in increasing the time to 
fatigue on a leg dynamometer. Brilla and Gunter (1995) failed to provide subjects with a 
washout period between interventions which may have had a negative effect on recorded 
results as levels of Mg2+ may not have returned to baseline level for the group experiencing 
placebo as their second intervention. 
Furthermore, it has also been suggested that endurance athletes may experience a state of 
Mg2+ deficiency when competing in long distance endurance events. It has been proposed 
that this state of Mg2+ deficiency may be caused by the increased Mg2+ losses catabolised 
by an increased sweat rate or as a result of increased Mg2+ requirements due to high 
habitual daily rates of energy expenditure (Terblanche et al., 1992). Therefore Mg2+ 
supplementation would be beneficial to prevent deficiency from occurring during ultra-
endurance sporting events.  
Terblanche (1992) assessed the effects that Mg2+ supplementation may have on 
performance in a marathon footrace. Twenty athletes were divided equally into two matched 
groups and were assessed four weeks prior to the event and six weeks post event. The trial 
was double blind with the experimental group receiving 365mg of Mg2+ daily. It was reported 
that Mg2+ supplementation did not increase either muscle or serum concentrations, following 
blood samples and muscle biopsy‟s consequently resulting in no positive effect on marathon 
performance. The lack of increase may be related to the level of Mg2+ provided to subjects 
as 365mg/daily may have not been adequate enough to promote a significant response.  
Research has proposed that substantial redistributions within the body may occur during 
bouts of exercise, resulting in losses of Mg2+ (Lukaski, 2000). When compared to pre-
exercise conditions a shift can be seen from the plasma into the red blood cells (Deuster, 
Dolev, Kyle, Anderson & Schoomaker, 1987). Deuster (1987) conducted a study and 
concluded that the direction and magnitude of Mg2+ redistribution in the circulation was 
influenced by the intensity of the exercise. Deuster (1987) stated that the greater the energy 
requirement from anaerobic or glycolytic metabolism, the greater the translocation would be 
of Mg2+ from the serum to the red blood cells.  
Another route of Mg2+ loss during exercise is via sweat and cellular exfoliation (Lukaski, 
2000). A trail conducted on men performing controlled work for 8 hours on cycle ergometers 
in temperatures of 40⁰C proceeded to lose 15.2-17.8mg Mg2+/d in sweat (Condolazio, 1983). 
This loss of Mg2+ equated to 4-5% of the individuals daily Mg2+ supporting the suggested 
theory that Mg2+ loss is at an increase during exercise.  
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As previously discussed Mg2+ may also have a positive effect on sports performance as it 
plays a vital role in muscle contraction. In a state of hypomagnesemia an individual may 
experience muscle cramping as it has been proposed that Mg2+ deficiency may cause 
cramps during exercise (Stamford, 1993). Bergeron (2003) reported that tennis players 
competing in hot and humid conditions may be susceptible to muscle cramping. Bergeron 
(2003) went on to say that extreme sweat loss in hot and humid conditions will lead to an 
increased loss in Mg2+ ultimately resulting in muscle cramping. Mg2+ supplementation should 
therefore aid in the prevention of such events occurring by increasing overall Mg2+ status 
(Bergeron, 2003).  
Golf et al (1993) conducted a study on female rowers, during which they were supplemented 
with either 360mg of Mg2+ aspartate or a placebo for a 3 week intervention. It was concluded 
that the athletes consuming Mg2+ had lower activities of total serum creatine kinase and 
creatine kinase isoenzyme from skeletal muscle after training in comparison to the placebo 
group. Furthermore it was also reported that the Mg2+ supplementation group had lower 
serum lactate concentrations and 10% lower oxygen uptake when performing a submaximal 
performance trial, concluding a positive impact on sports performance. Ripari (1989) 
conducted a similar trial, during which subjects were presented with either Mg2+ (250mg 
Mg2+/day) or placebo supplementation. Improved cardiorespiratory function during a 30 
minute submaximal exercise test was reported. These findings suggest that Mg2+ 
supplementation could provide a beneficial effect on work efficiency and muscle metabolism.  
Mg2+ supplementation has also been shown to improve muscle functioning. Brilla and Haley 
(1992) provided Mg2+ (Mg2+ oxide 8mg/kg day) or placebo to two groups of young men. They 
then assigned the participants with a seven week training programme which was to be 
followed alongside the supplementation plan. Total Mg2+ intakes for the Mg2+ intervention 
group were estimated to be 250/mg per day. Following the 7 week training programme peak 
knee-extension torque was assessed and it was reported that the Mg2+ intervention group 
had a greater increase when compared to the placebo group. This also suggests that Mg2+ 
may play a role in performance activities that require a predominant contribution of glycolytic 
metabolism. 
Lukaski (1983) recruited 44 healthy male university athletes and 20 untrained males for a 
study to assess maximal oxygen consumption, during a maximal treadmill test, in relation to 
Mg2+. Before conduction of the maximal treadmill test subjects were required to fast for a 
twelve hour period and provide an antecubital blood sample. Recorded weak, positive trend 
(r = +0.46, p < 0.002) between maximal oxygen uptake expressed per kg body weight and 
plasma Mg2+ in athletes as can be seen in figure 3.   
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Mechanisms of Magnesium 
Fig. 3. displays the relationship found between maximal oxygen consumption (VO2 max) and 
fasting plasma Mg
2+
 concentration in 44 male athletes (Lukaski, Bolonchuk, Klevay, Milne & 
Sandstead. 1983) 
The relationship reported between plasma Mg2+ and maximal oxygen consumption in the 44 
male athletes suggests the possible metabolic role of Mg2+ during exercise, other than its 
already acknowledged role as a co-factor in neuromuscular functioning (Shils & Shike, 
2006). 2,3-BPG is formed from 1,3-BPG by the enzyme BPG mutase. 1,3-BPG is created 
during the normal glycolytic pathway, which may be dephosphorylated by phosphoglycerate 
kinase. Magnesium may facilitate the delivery of oxygen to the working muscles by its 
involvement in the production of 2,3-diphosphoglycerate (2,3-DPG) in the erythrocyte 
athletes (Lukaski, Bolonchuk, Klevay, Milne & Sandstead. 1983). Scientific evidence has 
shown Mg2+ status to decrease during and shortly after long duration exercise in marathon 
runners (Rose, Carroll, Lowe, Peterson & Cooper, 1970; Noakes, Dennis, Marais & Eckert, 
1992) and cross country skiers (Refsum, Tveit, Meen, & Strömme, 1973). Serum Mg2+ levels 
were reported to have dropped by up to 10% after each race.  
In vitro studies have also shown correlations between erythrocyte 2,3-DPG and ATP and 
Mg2+ content of whole blood (Lukaski, Bolonchuk, Klevay, Milne & Sandstead. 1983). The 
30 
Luke Pitkin: 09201403 
production of 2,3-diphosphoglycerate (2,3-DPG) in the erythrocyte will increase the delivery 
of oxygen to the working muscles, thus increasing sports performance. The addition of Mg2+ 
ions to anticoagulated whole blood has been shown to increase the levels of 2,3-DPG 
content (Darley, 1979). Oken (1971) reported that there was a decreased level of 
erythrocytic Mg2+, a decreased glucose utilisation with reduced ATP and 2,3-DPG contents 
in a group of hypomagnesemic rats where spherocytic haemolytic anemia was described. In 
the circulation when Hb is deoxygenated there is a net increase in the amount of free Mg2+ 
ions within the erythrocyte which in turn causes the inhibition if the enzyme hexokinase to be 
relieved, thereby stimulating glycolysis and further production of 2,3-DPG (Oken, Lichtman, 
Miller & Leblond, 1971).  
Brewer (1969) indicated that in vivo only about 5% of the erythrocytic Mg2+ is unbound, and it 
is this free Mg2+ which may regulate glycolysis and 2,3-DPG production. The correlation 
coefficient (r= 0.46) calculated by Lukaski et al (1983) for the reported association of 
maximal oxygen consumption and plasma Mg2+ in the 44 male athletes indicates that 21% of 
the variance accounted for in the maximal oxygen uptake was due to the differences seen in 
plasma Mg2+. Thus, other factors accounted for the variance. Although as only 5% of 
erythrocyte Mg2+ may regulate the production of 2,3-DPG the 21% of the variance may 
identify that Mg2+ has an important effect (Lukaski, Bolonchuk, Klevay, Milne & Sandstead. 
1983). 
The relationship observed between maximal oxygen consumption, which is dependent on 
oxygen delivery to the working muscles, and plasma Mg2+ in the athletes may represent a 
cellular adaptation of Mg2+ metabolism to physical training. Studies have reported significant 
increases in erythrocyte 2,3-DPG in athletes after a single bout of short duration maximal 
activity (Taunton, Taunton, & Banister, 1973; Böswart, Kuta, Lisý, & Kostiuk, 1980). Whether 
these increases in 2,3- DPG were related to Mg2+ ion redistribution in the blood is not known.   
The influence that prolonged exercise will have on Mg2+ status must be taken into 
consideration. Prolonged exercise status will potentially facilitate a Mg2+ deficient state in the 
individual, due to an increased requirement notably promoted by a greater metabolic 
response to exercise and affiliated redistributions of Mg2+ within the body (Rayssiguier et al., 
1990).  
Hypomagnesemia and hypermagnesemia commonly occur as a result of Mg2+ redistribution 
catalysed by long duration, low intensity endurance exercise and short bouts of high intensity 
exercise (Bohl & Volpe, 2002). Hypermagnesemia is said to occur due to a decrease in 
plasma volume, subsequent cellular compartmental shifts increasing serum or plasma Mg2+ 
concentration due to acidosis and muscular contraction (Deuster, Dolev, Kyle, Anderson & 
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Schoomaker, 1987). Another suggested mechanism of hypermagnesemia is acidification, 
which is proposed to elicit an increased intracellular Mg2+ by influencing the dissociation of 
Mg2+ from its intracellular binding sites (Kim, Cho, Kang & Kim, 2006). 
Hypomagnesemia on the other hand has been linked to prolonged intense endurance 
exercise (Casoni, et al., 1990; Mooren, Golf, Lechtermann & Völker, 2005). It has been 
reported that during the state of exercise there will be a shift of Mg2+ onto three primary sites. 
Nielsen & Lukaski (2006) reported these three sites to be the erythrocytes, the adipocytes 
and the myocytes.  In regard to the erythrocytic Mg2+ shift that is supported  and contradicted 
by academic research, acknowledgements have presented an emphasis that the increased 
concentration of ionised Mg2+ within the erythrocyte highlights exercise and erythrocytic Mg2+ 
to modulate cellular signalling and energy metabolism (Nielsen and Lukaski, 2006). These 
reported increases in erythrocyte Mg2+ may coincide with previous research linking 
performance increments to the production of 2, 3-DPG, which is said to facilitate an 
increased maximal oxygen consumption due to the 2, 3-DPG function of sustaining sufficient 
haemoglobin oxygen affinity and oxygen transport (Lukaski, 1983).  
Despite the suggested enhancements and performance gains due to Mg2+, other research 
has reported an inverse relationship between erythrocyte Mg2+ and 2, 3-DPG (Resina et al, 
1994). Although, erythrocyte intracellular Mg2+ reported at 0.2mM in an oxygenated state has 
been shown to increase to 0.6mM due to haemoglobin dissociation Laughlin & Thompson, 
1996). Such a deoxygenation induced increase of Mg2+ corresponds to alleviating previous 
inhibitory actions on hexokinase, which will in turn stimulate glycolysis and the production of 
2, 3-DPG (Lukaski, 1983). This provides a greater potential for increased exercise 
performance, although this cannot be said to be definitive as there is still room for further 
investigation into the Mg2+ and 2, 3-DPG relationship.    
Although there are many controlled trials that support Mg2+‟s impact on physical activity there 
is still literature that contradicts the findings. Manore et al (1995) recruited recreationally 
active men who agreed to partake in a 12 week exercise programme, which predominantly 
consisted of aerobic activities. Subjects also consumed either Mg2+ (250mg/d) or placebo 
supplementation. Results reported an increase in peak oxygen uptake in both intervention 
groups thus resulting in the Mg2+ supplementation providing no significant effect. Therefore, 
these findings indicate that Mg2+ supplementation does not exert an independent effect on 
performance gains.   
These findings suggest that Mg2+ supplementation may not be effective in improving 
cardiovascular sporting performance although further investigations are needed into this 
area.  
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10 kilometre run  
Testing performance is one of the most common and important measures tested in sports 
science and physiology research (Currell & Jeukendrup, 2008). Performance testing allows a 
controlled stimulation of sports performance for scientific purposes. There are three main 
contributing factors that define a good performance test validity, reliability and sensitivity 
(Currell & Jeukendrup, 2008). A valid protocol is the one that closely resembles the 
performance that is being stimulated. When testing for race type events there are two main 
methods that are used, these are time trial and time to exhaustion tests (Currell & 
Jeukendrup, 2008). Time trials are said to have greater validity than time to exhaustion trials 
due to the fact that they provided a good stimulation of actual performance. Games sports 
such as football and tennis are harder to simulate due to constant changes in intensity and 
direction (Currell & Jeukendrup, 2008).  
Research has shown that time to exhaustion protocols have a coefficient of variation of 
>10%, whereas time trials are more reliable as they have been shown to have a coefficient 
of variation of <5% (Currell & Jeukendrup, 2008). 
Validity 
There are three types of validity that can be applied to performance protocols logical validity, 
criterion validity and construct validity (Currell & Jeukendrup, 2008). Logical validity also 
known as face validity assesses whether a test measures achieves what it is intended to 
measure, although this can be difficult to assess (Thomas, Nelson & Silverman, 2011). 
Criterion validity allows for an objective measure of validity. There are two different types of 
criterion validity concurrent and predictive (Thomas & Nelson, 2001). Concurrent validity 
assess that the performance protocol is correlated with a criterion measure (Thomas & 
Nelson, 2001). Predictive validity involves using a performance protocol to subsequently 
predict performance (Thomas & Nelson, 2001). Construct validity refers to the degree in 
which a protocol measures a hypothetical construct, in this case performance. It can be 
measured by comparing two different groups of subjects with varying abilities (Thomas & 
Nelson, 2001).   
The use of time trials as a measure of performance is very common in sports physiology 
research (Currell & Jeukendrup, 2008). For a performance protocol to be a logically valid 
measure of performance it must aim to measure the performance in question. Therefore, a 
time trial protocol will have a high level of validity when researching race events such as 
cycling and running (Currell & Jeukendrup, 2008). Foster et al. (1993) showed that there was 
no physiological difference in a 5-km time during a laboratory trial when compared to actual 
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performance. Laursen at al. (2002) investigated the relationship of exercise test variables to 
Ironman triathlon cycling performance. Laursen et al (2002) concluded that there was no 
significant correlation between the time to exhaustion trial and cycling performance in an 
Ironman triathlon.  
Time trials have been shown to correlate well with actual performance in both cycling 
(Palmer, Dennis & Noakes, 1996) and running (Russel, Redmann & Ravussin, 2004). 
Palmer et al (1996) found a strong relationship between time to completion for a 40-Km 
cycling trial performed on a Kingclye ergometer compared with time to completion of two 
outdoor 40-Km time trials. Russel, Redmann & Ravussin (2004) reported that completion of 
a 10-Km running time trial after a 90 minute preload at 65% VO2max was found to have a high 
correlation (r = 0.95) with the time taken to complete a 10-Km road race. Although further 
research is needed to help establish these relationships, the absence of a relationship 
between time to exhaustion and performance (Laursen, Rhodes & Langill, 2002) and the 
present relationship between time trail and performance (Palmer, Dennis & Noakes, 1996; 
Russell, Redmann & Ravussin, 2004) would suggest that time trials are a valid measure of 
running performance.   
There are two main types of time trail that could be used. The target could be set at distance 
or work (Currell & Jeukendrup, 2008). An advantage of using an at distance target is that it 
provides a more valid representation of actual performance. The use of an at work target, 
whilst not as valid as a distance target allows for a performance test with higher levels of 
control (Currell & Jeukendrup, 2008).  
Reliability  
Reliability is another important measure as it gives an indication of the biological and 
technical variation of the protocol (Bagger, Petersen & Pendersen, 2003). Measure of 
reliability can be used to calculated the necessary sample size for a given effect size, 
therefore, reducing the risk of potential errors occurring (Atkinsin & Nevill, 1998). There are 
various ways in which reliability can be expressed. The common measure of reliability used, 
is the coefficient of variation (CV). This expresses the standard deviation (SD) of the 
measure as a percentage of the mean, making it a lot easier to compare the amount of 
variation between various protocols (Currell & Jeukendrup, 2008). Other measures that can 
also be used are Pearson‟s product moment correlation (r) in which a high significant 
correlation can lead to the conclusion that a specific protocol is reliable. The intraclass 
correlation coefficient (ICC) is an additional form of correlation that can be used to asses 
reliability. 
34 
Luke Pitkin: 09201403 
Most research in the field of performance protocols has investigated into one type of 
protocol. Jeukendrup et al (1996) compared the reliability of various performance testing 
protocols. They compared time to exhaustion and time trial protocols and concluded that the 
time to exhaustion has poor reliability when compared with time trails and constant duration 
protocols. The findings by Jeukendrup et al (1996) suggest that the time trial approach being 
adopted in the current trial would provide greater reliability than a time till exhaustion trial.   
Sensitivity  
When choosing a protocol it is important that the smallest worthwhile effect can be detected. 
(Currell & Jeukendrup, 2008). Analysis of the finishing times for the 2004 Athens Olympics 
cycling time trail shows that the difference between first and second place was 0.52%, 
suggesting that the small gains in performance can lead to massive changes in the outcome 
of a race. Hopkins et al (1999) used mathematical models of finishing times of the 1997 
international Amateur Athletics Federation series to look at the smallest worthwhile increase 
in performance. It was concluded that in order to increase the chance of winning by 10%, the 
intervention must increase the athlete‟s performance by 0.3 times the athletes CV between 
events. For this to increase to 20% the smallest worthwhile enhancement is 0.7 X CV. 
Jeukendrup and Martin (2001) used a mathematical model to look at the improvements that 
different interventions can have upon cycling a time trail performance. It was suggested that 
even the largest training effects may improve time trial performance in elite cyclists by 2% 
with nutritional interventions producing smaller effects. Therefore, it could be deemed useful 
to be able to detect these small improvements that interventions can make (Currell & 
Jeukendrup, 2008).  
Validity, reliability and sensitivity are all interlinking factors; they are not separate. A protocol 
can be reliable, but not valid where as a valid protocol must be reliable (Atkinson & Nevill, 
1998). The relationship between reliability and validity is such that a reliability correlation 
coefficient is the square of the validity correlation coefficient (Thomas & Nelson, 2001). Even 
taking all this into consideration it must be remembered that any effect see in a test of 
performance conducted in a laboratory may not transfer directly to an actual performance 
situation. Jeukendrup at al (1997) showed an increase in the time taken to complete a 
laboratory based 1 hour time trial of 2.3% due to carbohydrate feeding; however would the 
same subjects experience the same gains of performance in a real competition? The 
relationship between the size of the effect seen in laboratory situations and the size of the 
effect that occurs is still unknown, but could still be a very important relationship to 
understand (Currell & Jeukendrup, 2008). 
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Factors to control in a protocol 
Familiarisation  
When conducting research there are many different factors that need to be taken into 
consideration (Currell & Jeukendrup, 2008). Firstly subjects should be familiarised with the 
protocol and equipment being used. Jeukendrup (1996) did not show any learning effect 
over six trials for a time trial lasting approximately 40 minutes. This may have been due to 
the fact that participants were trained cyclists that may have been used to the laboratory 
environment and testing procedures. However Laursen et al (2003) showed a learning effect 
for a 40-Km time trial. It was seen that when the first trial was compared with the third trial 
the CV was 2.9% compared with 0.9% when the second trial was compared with the third 
trial. Therefore, it may be suggested that subjects are familiarised with the protocol and 
equipment prior to the conduction of the protocol to prevent this learning effect from 
occurring. 
Measurements  
It has been previously reported that taking physiological measurements during a 
performance protocol will interfere with the personal performance of the subjects; this has 
also been linked to having an effect on concentration (Currell & Jeukendrup, 2008).  
There have been many methods that have been adopted in an attempt to measure 
performance as accurately as possible. Traditionally, researchers have attempted to assess 
endurance performance with a debate about whether a time to exhaustion or time trail 
protocol is the most appropriate. Time trails appear to have a lower variation when 
compared to time to exhaustion suggesting that they would provide a more valid account of 
what could occur in sporting performance. This form of protocol will be adopted in this 
investigation as subjects will be required to complete a 10-Km time trial. 
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Method 
Pre experimental 
Pilot Study Before commencing with the trial pilot testing was conducted on 4 participants to 
assess whether the protocol design would be effective, after the pilot testing was conducted 
the protocol was reviewed and adjusted. The original protocol involved several physical trials 
and lasted approximately 150 minutes. This was deemed to be too long and taxing on 
participants so the isometric leg dynamometer trial was removed accordingly. Blood 
pressure recording during exercise was also removed from the protocol as it was deemed 
too hard to ascertain blood pressure recordings whilst a participant was running on a 
treadmill, although blood pressure was still recorded before and after the 10 kilometre run. 
G Power Calculations Before subject recruitment was conducted a power test was 
performed using a sample power software (SPSS SamplePower 3, IBM, Porthsmouth, 
United Kingdom) utilising pervious data on blood pressure (Cappuccio, Markandu, Beynon, 
Shore, Sampson, & MacGregor. 1985; Jee, Miller, Guallar, Singh, Appel, & Klag. 2002). 
Results indicated that a sample size of fifteen participants per intervention group would be 
sufficient to achieve a power score of 0.80 (see appendix). 
Participants 
Participants. 
Fifteen subjects were initially screened and accepted for participation. During the protocol 
two subjects dropped out, failing to complete. This left nine male and four female subjects 
who were successful in completing the protocol, characteristics of all subjects can be seen 
below (Table 5). The two subjects that failed to complete the study did so due to injury and 
the arrival of a child.  
Table. 6 Characteristics of the 13 studied participants  
        
Age (Years) 
 
24.85±6.49 
Height (cm) 
 
175±10.34 
Weight (Kg) 
 
71.9±11.46 
VO2 max (ml/Kg/min) 48.77±6.87 
One Rep Max (Kg) 
 
64.62±26.65 
Mg Serum 
(mmol/L)   0.71±0.05 
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Once written informed consent was obtained from the school of Life and Medical Science 
Ethics Advisory Committee, University of Hertfordshire, fifteen apparently healthy, physically 
active participants (Age: 24.85 ± 6.49 years, Height 175 ± 10.34 cm, Weight: 71.9 Kg ± 
11.46 Kg) were recruited from the county of Hertfordshire. Participants were sourced via a 
recruitment letter and e-mail that was circulated to local running and athletics clubs. These 
were targeted in an attempt to recruit a selection of participants that would be successful in 
completing the 10 kilometre run.  
Before the selection of participants occurred a screening process was conducted to ensure 
all participants met the inclusion criteria. Selection criteria for inclusion in the trial included, 
males and females, individuals between the ages of 18-40, to be recreationally active, have 
no clinical history of hypertension, the expectation and willingness to attend the University on 
five separate occasions, the expectation and willingness to record a four day food diary, the 
expectation and willingness to consume 500mg of both Mg2+ (80mg elemental) and cornflour 
daily. Exclusion criteria included participants that suffered from high blood pressure, 
participants that had any underlying heart problems, participant‟s that had experienced a 
cold two weeks prior to the trial. Participants eligibility was assessed using a health screen 
questionnaire approved by the ethical committee of Life Sciences at the University.  
The participants were then familiarised with the equipment Participants returned later that 
week to undertake a VO2 max test and a one repetition max test. The VO2 max test was 
conducted on the treadmill, it commenced on 8 kilometres per hour, with no incline. The 
speed and incline were increased alternately on every minute by 1% or 1 kilometre per hour 
until the participant could no longer maintain a state of exercise. All participants were 
verbally encouraged to continue for as long as possible and their VO2 max was recorded at 
the end. The mean VO2 max scores achieved were 49.9 ± 7.54 ml/min/Kg for the male 
participants and 47.5 ± 4.65 ml/min/Kg for the female participants. McArdle, Katch and Katch 
(2012) report several fitness categories relating to VO2
 
max scores. The average VO2
 
max 
scores achieved in this trial by both males and females falls into the good category. This 
confirms that the sample of participants who undertook the trial were good recreational 
athletes of similar fitness levels. 
The one rep max score was attained after the subjects had recovered from the VO2 max test. 
This trial involved subjects performing a maximal voluntary contraction, bench press lift. This 
trail was conducted in the lifting cage with the safety bars correctly positioned and two 
researchers were present for safety and to help spot the lift. Each participant was started on 
a light weight, with increments of 2.5kg each time. Participants were allowed 5 minutes rest 
between lifts to allow for ATP restoration. The mean one repetition max scores achieved 
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were 64.62Kg ± 26.65Kg. The one rep max trial was conducted so that 75% and 50% of the 
max score could be calculated for later use in the protocol. The two tests provided an 
indication as to the overall fitness level of the 13 participants and the maximum weight that 
could be lifted in one all out bench press exertion. 
A week later participants were required to return to the University to commence with the 
protocol. The protocol design was as follows; on arrival subjects were asked to complete a 
health screen questionnaire to confirm that they were feeling fit and able to participate. They 
were then left in the seated position for 5 minutes before having a blood pressure reading, 
recorded using an electronic blood pressure monitor (Digital Automatic Blood Pressure 
Monitor, Omron, Milton Keynes, United Kingdom).  
After the blood pressure reading had been conducted participants partook in the bench 
press trial. This trial involved participants performing as many bench press repetitions as 
possible until failure, commencing with 75% of 1RM followed directly after by 50%. Before 
commencing with the lift participants were provided with time to warm up by completing a set 
of repetitions on 40% of their one repetition max scores. The lifting cage was prepared 
before conduction of testing by assuring that the safety bars were correctly set preventing 
participants from dropping the weight on their chest. Two spotters were also present. 
Participants then started with 75% of their one rep max scores and performed that until 
failure. This was followed by 50% of their one rep max; this was also performed a bench 
press until failure. During the trial total repetition count was being recorded by the researcher 
whilst mean and peak displacement (M/sec), mean and peak speed (M/sec), mean and peak 
power (N) and mean and peak force (N) were all being measured by the Globus Ergo 
System (Ergo System, Globus, Codognè, Italy). 
Following the bench press participants proceeded to run the 10 kilometre trial. The run was a 
time trial, thus participants were able to manipulate the pace that they were running at, 
aiming to complete the distance in as short a time as possible. Before commencing with the 
trial participants were required to put on a cortex gas mask and heart rate monitor (Polar, 
Warwick, England) for analysis to be conducted throughout the duration of the run. 
Respiratory analysis was recorded by a cardiopulmonary exercise testing system (Cortex 
Metalyzer, Cortex, Leipzig, Germany). A Borg scale rating of perceived exertion (RPE) was 
another variable measured throughout the 10 kilometre running trial (Borg, 1982).  
During the 10 kilometre running trial respiratory readings were recorded at 10 minute 
intervals from the metalyser (Cortex, Leipzig, Germany). At every 10 minutes the researcher 
would record V‟O2 (L/Min), V‟O2/Kg (ml/Min), breathing frequency, V‟E/V‟O2 equivalent for O2 
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uptake, V‟E (L/min) minute ventilation & RER (respiratory exchange ratio). Distance 
achieved and RPE at each 10 minute interval was also recorded.  
Following completion of the 10 kilometre trial, participants were provided with time to cool 
down adequately and re-hydrate before returning to the bench press to complete the trial for 
a second time. Once the bench press trial had been conducted again at 75% and 50% of 
ORM subjects had blood pressure recorded for a second and final time.  
Finally after completion of all physical trials and blood pressure readings a venous blood 
sample was collected. Subjects were required to sit upright in the phlebotomy chair with their 
right arm resting on the required stand. A tourniquet was applied and tightened accordingly. 
After the correct point of insertion was located the sight was cleaned with a sterile wipe to 
ensure that the sight was clean. Blood samples were collected using a standard butterfly 
needle (Williams Medical, Butterfly Needle, United Kingdom) and collected into a 5ml gold 
vacutainer, containing a clot activator and gel for serum separation. Once the vacutainer had 
been successfully filled the needled was removed and appropriately disposed of in a 
regulated sharps bin. Cotton wool was placed on the insertion site and pressure was applied 
until bleeding stopped.  
Five minutes after blood samples had been collected participants were able to leave and 
were provided with food diaries and supplementation before departure. Supplementation 
was provided in capsule form, with each capsule containing 500mg of Mg2+ citrate. After 
subject departure blood samples were spun at 10‟000 rotations per minute for a period of 10 
minutes in a blood centrifuge allowing separation of the blood due to the clot activator 
located in the vacutainer. Serum samples where then transferred into a plastic sample tube, 
successfully sealed, labelled and stored in a freezer at -73⁰C for later analysis.  
Following the completion of the testing the blood samples were transported from the 
University of Hertfordshire to Hemel Hempstead hospital for analysis of the Mg2+ content. 
Analysis was conducted using the Cobas 8000, modular analyser series (Roche 
Diagnostics, Rotkreuz, Switzerland). Four samples were deemed to be faulty and were 
returned without a Mg2+ level. 
Food diaries were recorded to provide an indication of the level of Mg2+ consumed by each 
participant through their diet. Dietary analysis was conducted with the aim of comparing the 
effects Mg2+ supplementation had on participants achieving adequate Mg2+ status through 
their diets against participants achieving a deficient Mg2+ status through their diets, as it has 
been suggested that Mg2+ supplementation will provide no further benefit to those achieving 
optimal Mg2+ status through their diet. 
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The design of the study involved the participants completing the protocol a total of four times 
over a fourteen week period. Participants were tested initially as a baseline measurement. 
Subjects were then provided with supplementation, either 500m/g of placebo or magnesium 
which was picked at random, resulting in 8 subjects initially consuming placebo and 5 
subjects consuming Mg2+. Supplementation was presented in capsule form and subjects 
were asked to consume one daily for a period of four weeks. The capsules had been 
separated and mixed up then placed into bags labelled A and B, this ensured that the 
interventions were blinded to both researchers and participants. After the four week 
supplementation period participants returned to the University to have post intervention 
testing conducted. Following this, participants had a five week washout period aiming to 
reduce any potential performance gains attained from the intervention and bring subjects 
back to baseline levels. After the washout period participants returned for a third time to 
complete a second set of baseline testing, participants were then presented with their 
second intervention. As the study was of a crossover design it was ensured that participants 
experienced both the placebo and magnesium interventions. After the final supplement 
intervention had been completed, participants returned one last time to conduct the protocol. 
A summary of this fourteen week testing period can be seen below (see table 6). 
Table 6. An overview of the requirements of participants during the 14 week study. 
Week 0 Week 1-4 Week 5-10 
Familiarisation to machines, 
exercises and VO2 max test. 
Returned later in the week to 
complete VO2 max and one 
repetition max test, which was 
used for baseline data. 
Pre-testing, maximal testing, 
baseline and initial venous 
bloods were collected.  
Supplementation was ingested 
which lasted a duration of 4 
weeks, whilst recording a three 
day food diary. Initial 
intervention testing to be 
conducted on sight at the 
University at the end of week 4 
during which a second blood 
was taken.  
Washout period, during which 
subjects consumed no 
supplementation  
Week 10 Weeks 11-14  
Second baseline testing was 
conducted subjects were asked 
to return to conduct same 
procedure. Third venous 
bloods were taken.  
Alternative supplementation to 
be consumed lasting a duration 
of 4 weeks. Final intervention 
testing to be conducted on 
sight at the University at the 
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Data Analysis  
Data analysis was conducted using SPSS (IMB, SPSS, United States) software. Before 
analysis could be conducted averages were calculated for each variable. Data was then 
analysed using a Repeated Measures Anova to conclude if recorded results contained 
significant differences. Standard deviation, Standard error and percentage change were also 
calculated alongside the significance levels and data was presented in graph and table 
format.  
Dietary analysis was conducted using DietPlan 6 following the collection of the food diaries. 
Dietary analysis was conducted with the aim of assessing whether Mg2+ supplementation 
would impact those achieving optimal Mg2+ status when compared to those achieving a 
deficient Mg2+ status through their diet.  
  
end of week 14 during which 
the final blood will be taken.  
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Results  
The mean plasma Mg2+ level at baseline was 0.71 mmol/L, this is below the mean serum 
concentration in humans, which has been suggested to be roughly 0.85 mmol/L (Wacker, 
1980).  
Mg2+ blood serum level 
Figure 4 displays the average pre and post Mg2+ blood serum level (mmol/L) for all 
participants in each intervention.  
 
Fig. 4. A comparison of average Mg
2+
 blood serum level (mmol/L) between both interventions 
at baseline and post intervention stage. Values are means ± SEM.  
No significance was seen between any of the groups although there was a 5.7% 
(0.04mmol/l) increase from pre to post Mg2+ intervention but this did now show significance 
(P=0.741).  
This finding shows a trend as Mg2+ appears to increase after the Mg2+ supplementation 
intervention. An increase of 0.02 (3.7%) mmol/L was also seen when post Mg2+ stage was 
compared to the post placebo stage and an increase of 0.03 (4.6%) mmol/L when compared 
to the pre placebo stage.  
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10 kilometre time trial completion time 
Figure 5 displays the average completion time recorded for all subjects‟ pre and post Mg2+ 
and placebo interventions.  
 
Fig. 5. Comparisons of average completion time of a 10 kilometre run (min:sec). Values are 
means ± SEM. * =P<0.05, concluding that a significance was seen between the post Mg
2+
 
intervention and all other intervention stages. 
Pre Placebo completion time was recorded as 00:57:59 ± 00:07:43 min:sec, post placebo 
completion time was recoded as 00:57:43 ± 00:07:20 min:sec. Pre Mg2+ completion time was 
recoded as 00:56:58 ± 00:06:59 min:sec whilst post Mg2+ completion time was recorded as 
00:55:58 ± 00:06:54 min:sec.  
Following the Mg2+ intervention there was an average decrease in 10K completion time of 
exactly 1 minute (1.77%) Following completion of a Repeated Measures Anova the decrease 
in completion time was deemed significant at P=0.001. 
When post placebo intervention was compared to pre placebo intervention a decrease of 16 
seconds (0.27%) was seen in completion time, this did not show significance (P=0.10).   
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Average heart rate 
During the completion of the 10 K time trial subject‟s heart rate was recorded at 10 minute 
intervals. Figure 6 displays the average heart rate (BPM) calculated from the readings taken 
at each 10 minute interval that was recorded pre and post both Mg2+ and placebo 
interventions. 
 
Fig. 6. A comparison of average heart rate (BPM) during the running time trial at each 
intervention stage, both baseline and post intervention. Values are means ± SEM. * =P<0.05, 
concluding that a significant difference was seen between the post Mg
2+
 intervention and the 
post placebo intervention.  
Pre placebo average heart rate recorded was 169.21 ± 9.82 BPM, post placebo average 
heart rate was recorded as 172.09 ± 8.74 BPM, pre Mg2+ average heart rate was recorded at 
169.49 ± 8.56 BPM and post Mg2+ average heart rate was recorded at 169.51 ± 8.56. 
Following the Mg2+ intervention period there was a slight decrease average heart rate by 
0.01 BPM (0.007%) when post Mg2+ was compared to Mg2+ baseline. Although the difference 
between the pre and post Mg2+interventions was not significant. A significant increase in 
heart rate would be expected alongside the significant decrease in 10 kilometre completion 
time. Significance was seen between post Mg2+ intervention and post placebo intervention 
(P=0.03), a decrease of 2.58 BPM (2.58%). This further supports an increase in 
performance and efficiency as participants achieved a significantly faster 10 kilometre 
completion time with a significantly lower heart rate when post Mg2+ and post placebo 
interventions are compared.    
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Average systolic blood pressure pre run 
Figure 7 displays the average resting systolic blood pressure measurement (mmHg) 
calculated from each participant‟s systolic blood pressure score recorded prior to conduction 
of the time trial run.  
 
Fig. 7. A comparison of average systolic blood pressure (mmHg) recorded before the 
conduction of the time trial for each intervention, both baseline and post intervention. Values 
are means ± SEM.  
Average systolic blood pressure pre placebo intervention was recorded as 130.69 ± 7.81 
mmHg, post placebo average blood pressure was recoded as 131.30 ± 11.12 mmHg. Pre 
Mg2+ average blood pressure was recorded as 131.69 ± 10.63 mmHg and post Mg2+ 
average blood pressure was recorded as 126.08 ± 7.37.   
Following the Mg2+ intervention period there was an average decrease in systolic blood 
pressure (mmHg) by 5.62 mmHg (4.26%) This difference was not deemed to be significant. 
(P =0.262). 
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Figure 8 displays the average systolic blood pressure measurement (mmHg) calculated from 
each participant‟s systolic blood pressure score recorded after the completion of the time 
trial run.  
Fig. 8. A comparison of average systolic blood pressure (mmHg) recorded after completion of 
the time trial at pre and post, both Mg
2+
 and placebo interventions. Values are means ± SEM. * 
=P<0.05, concluding that a significant difference was seen between the post Mg
2+
 stage and 
the post placebo stage. 
Average systolic blood pressure post run, recorded pre placebo intervention was 128.85 ± 
8.88 mmHg, post placebo average blood pressure was recorded as 133.46 ± 13.2 mmHg, 
showing no significant change as would be expected. Pre Mg2+ average blood pressure was 
recorded as 127.07 ± 11.8 mmHg, and post Mg2+ average blood pressure was recorded as 
125.23 ± 9.22 showing an average decrease in systolic blood pressure by 1.85 mmHg 
(1.45%)  But this was still not large enough to show a significance difference. 
When post Mg2+ was compared to the post placebo intervention there was a significant 
decrease of 8.23 mmHg (6.17%) (P=0.05) The comparison made between the placebo and 
Mg2+interventions is possible due to the similarity between the baseline readings.  
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Figure 9 displays the average diastolic blood pressure measurement (mmHg) calculated 
from each participant‟s diastolic blood pressure score recorded prior to the completion of the 
time trial.   
 Fig. 9. A comparison of average diastolic blood pressure (mmHg) recorded prior to the 
completion of the time trial pre and post both Mg
2+ 
and placebo interventions. Values are 
means ± SEM. *=P<0.05 vs. post placebo and baseline Mg
2+
 concluding a statistical significant 
difference. 
Average diastolic blood pressure pre placebo was recorded as 68.38 ± 7.99 mmHg, post 
placebo average blood pressure was recorded as 73.84 ± 11.1 mmHg, pre Mg2+ average 
blood pressure was recorded as 71.69 ± 12.65 mmHg and post Mg2+ average blood 
pressure was recorded as 63.61 ± 14.22 mmHg.   
Following the Mg2+ intervention period there was an average decrease in diastolic blood 
pressure by 8.08 mmHg (11.26%) when post Mg2+ was compared to Mg2+ baseline. This 
decrease was deemed to be significant P=0.0004 
When pre placebo was compared to post placebo there was an increase in blood pressure 
5.46 mmHg. This increase was not deemed to be significant P=0.19. In comparing post Mg2+ 
intervention to post placebo a decrease of 10.23 mmHg (13.85%) was recorded. This was 
the largest decrease seen between the interventions (P=0.03).  
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Average Diastolic blood pressure post run 
Figure 10 displays the average diastolic blood pressure measurement (mmHg) calculated 
from each participant‟s diastolic blood pressure score recorded after the completion of the 
time trial.  
Fig. 10. A comparison of average diastolic blood pressure (mmHg) recorded after the 
completion of the running time trial at pre and post both Mg
2+
 and placebo interventions. 
Values are means ± SEM. *=P<0.05 when post Mg
2+
 intervention is compared pre placebo 
intervention concluding a statistical significant difference.  
Average diastolic blood pressure post run, pre placebo was recorded as 72.92 ± 8.5 mmHg, 
post placebo average blood pressure was recorded as 71 ± 9.09 mmHg, pre Mg2+ average 
blood pressure was recorded as 69.54 ± 9.02 mmHg and post Mg2+ average blood pressure 
was recorded as 67.54 ± 6.32. 
Following the Mg2+ intervention period there was an average decrease in diastolic blood 
pressure (mmHg) by 2 mmHg (2.88%) when post Mg2+ was compared to pre Mg2+ 
intervention but no significance was found (P=0.41). When post Mg2+ was compared to pre 
placebo intervention there was a recorded decrease of 5.38 mmHg (7.38%). This was the 
largest difference seen and after conduction of a repeated measure Anova it could be 
concluded that the reduction in diastolic blood pressure recorded at the post Mg2+ 
intervention was of significance P=0.008 when compared to the pre placebo intervention 
stage. 
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Average VO2  
During the time trial run VO2 (ml/Kg/min) was recorded at 10 minute intervals. Figure 11 
displays the average VO2 readings recorded pre and post both Mg
2+ and placebo 
interventions.  
 
Fig. 11. A comparison of VO2 recorded during the running time trial (ml/Kg/min) at each 
intervention stage, both baseline and post intervention. Values are means ± SEM.  
Average VO2 pre placebo intervention was recorded as 37.89 ± 9.16 ml/Kg/min, post 
placebo average VO2 was recorded as 40.86 ± 7.5 ml/Kg/min showing no significant 
difference as would be expected. , Pre Mg2+ average VO2 was recorded as 39.85 ± 7.1 
ml/Kg/min and post Mg2+ average VO2 was recorded as 41.22 ± 5.66 ml/Kg/min, this also did 
not show a significant change. 
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Mean power  
Figure 12 displays the average mean power recorded at 75% and 50% of 1RM during the 
bench press trial, conducted pre and post completion of the 10K run for both Mg2+ and 
placebo interventions.  
 
Fig. 12. A comparison of mean power recorded pre and post the running time trial (Watts) at 
75% and 50% of participants ORM at each intervention stage, both baseline and post 
intervention. Values are means ± SEM.  
Following the Mg2+ intervention there was increases in power in all trials except the mean 
power 50% post run. All results recorded had no significance. 
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Peak power  
Figure 13 displays the average, peak power recorded at 75% and 50% of ORM during the 
bench press trial, recoded pre and post completion of the 10K run for both Mg2+ and placebo 
interventions.  
Fig. 13. A comparison of peak power recorded pre and post the running time trial (Watts) at 
75% and 50% of participants ORM at each intervention stage, both baseline and post 
intervention. Values are means ± SEM.  
Following the Mg2+ intervention there was increases in power in all trials, when pre and post 
Mg2+ interventions are compared although all results recorded had no significance. The 
lowest P value was seen between the pre and post Mg2+ interventions at 75% of ORM after 
the completion of the time trial P=0.07. This shows a trend between the increases in power 
following Mg2+ supplementation.    
Throughout the protocol different variables were recorded in both the bench press trial and 
running time trial. Table 7 displays an overview of the mean results recorded in the bench 
press and running time trials.  
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Table 7. Average results recorded during the bench press trials and running time trials and the lowest 
P values seen after conduction of a Repeated Measures Anova * = Significance found. 
 
        
Variable Investigated  Pre Placebo Post Placebo  Pre Mg  Post Mg 
          
Breathing Frequency (RR) 54.83±7.31 56.29±8.02 55.03±8.36 57.78±6.9 
Mean Force Pre Run 75% 
(N) 521.85±199.5 534.54±181.36 515.77±199.58 525.77±199.24 
Mean Force Pre Run 50% 
(N) 331.69±135.63 345.84±119.64 335.69±138.26 338±138.91 
Mean Force Post Run 75% 
(N) 514.54±199.65 540.92±181.19 504.53±203.75 519±194.67 
Mean Force Post Run 50% 
(N)  383.46±150.5 415.69±162.19 370.76±144.25 381.07±153 
Peak Force Pre Run 75% 
(N)  594.15±227.96 598.84±192.98 600.61±239.19 612.15±239.27 
Peak Force Pre Run 50% 
(N)  417±169.98 434.07±155.45 426.23±174.16 412.69±170.64 
Peak Force Post Run 75% 
(N)  602.76±241 631.76±218.41 595.84±249 621.61±263.3 
Peak Force Post Run 50% 
(N)  473±196.5 496.61±180.33 465±194.22 472.76±193.92 
Reps Pre Run 75% * 9.46±3.53 8.846±3.46 9.92±3.98 10.76±3.72 
Reps Pre Run 50%  17.61±5.18 18±4.56 16.3±5 16.84±5.77 
Reps Post Run 75%  7.69±3.98 7.38±3.81 8.15±2.67 8.3±2.98 
Reps Post Run 50%  14.92±5.7 14.3±4.83 14±4.52 14.84±4.72 
V'E (L Per Min) * 82.87±27.88 89.05±27.73 89.62±24.66 94.39±21.69 
V'E (VO2) * 27.54±3.51 28.35±3.85 28.46±3.21 29.85±2.64 
 
Blood serum samples were collected pre and post both Mg
2+
 and placebo interventions (mmol/l). 
Table 8 displays the Mg
2+
 serum levels that were recorded both pre and post both Mg
2+
 and placebo 
interventions.  
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Table 8. Average Mg2+ serum levels recorded pre and post both Mg2+ and placebo 
interventions (mmol/l).  
 
          
 
 
Participant  Pre Placebo 
Post 
Placebo Pre Mg Post Mg  
 
  
0.71 mmol/l 0.72 mmol/l 0.7mmol/l 0.74 mmol/l 
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Table 9. Average Mg2+ consumption achieved by each participant, recoded during the four 
day food diary. Analysis was conducted using Dietplan6.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
      
Subject  Gender   
1 Male 275mg 
2 Male 156mg 
3 Male 477mg  
4 Female 264mg  
6 Male 296mg 
7 Male 254mg 
8 Female 306mg 
9 Male 219mg 
12 Male 311mg 
14 Male 384mg  
15 Female 192mg 
18 Female 243mg 
19 Male 101mg  
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Discussion  
The current study aimed to examine the hypothesis that Mg2+ supplementation may have a 
significant performance effect on recreationally active males and females running a 10 
kilometre time trial and conducting a bench press trial until fatigue when ingesting 500mg 
Mg2+ daily for a 4 week period. Alongside performance improvements this current study also 
looked to assess Mg2+ supplementations impact on blood pressure and Mg2+ levels in blood 
serum. The protocol design was based around the rationale that Mg2+ may facilitate the 
delivery of oxygen to the working muscles by the production of 2,3-diphosphoglycerate (2,3-
DPG) in the erythrocyte (Lukaski, Bolonchuk, Klevay, Milne & Sandstead. 1983), and that 
Mg2+ may play a pivotal role in reducing blood pressure by its  impact on vascular smooth 
muscle cell tone, reactivity and contractility (Laurant, & Touyz, 2000; Touyz, 2003; 
Barbagallo, Dominguez, Galioto, Cani, Malfa, & Paolisso, 2003). 
Mineral elements, such as Mg2+, are required by the human body in modest amounts for the 
maintenance of health and the development of optimal functioning (Lukaski, 1995). Mg2+ 
supplementation has become increasingly popular as Mg2+ is a cofactor to over 325 
enzymatic reactions occurring within the body (Newhouse & Finstad, 2000). This suggests 
that deficiency of the mineral may have various physiological and exercise performance 
implications (Newhouse & Finstad, 2000; Wolf & Cittadini, 2003). 
Results showed that a four week Mg2+ intervention was successful in decreasing the time 
taken to complete a 10 kilometre run. The significant decrease in performance time may be 
due to the Mg2+ supplementation period and various pathways, although at this point the 
source of the physiological adaptation is still unknown. A lot of control was put into place 
regarding previous exercise as most subjects were competitive runners, partaking in regular 
activity although less control was put into place regarding the participant‟s diets including 
alcohol consumption. The mean dietary intakes of Mg2+ seen in males was 274.77mg ± 
113.15mg,  whilst the female food diaries reported an average Mg2+ intake of 251.25mg ± 
47.39mg. The Mg2+ intake recorded in the food diaries fell below the recommend daily intake 
of 300mg/day for adult males and 270mg/day for adult females (COMA, 1991). Altura (1994) 
reported that inactive females ingest approximately 175-225mg/day of Mg2+, whilst Lukaski 
(1995) reported that female athletes would consume around 168-182mg/day of Mg2+. 
Therefore it would seem that participants taking part in the current study were consuming 
intakes that were higher than the normal, but still below the recommended daily allowance. 
Apart from being recreationally active and between the ages of 18-39 the participants 
appeared to be diverse when it came to the dietary analysis. Some participants reported 
very healthy diets, whilst others tended to consume highly processed foods that have a lack 
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of Mg2+ content. In addition, as there was no correlation between Mg2+ in the diet and Mg2+ 
Serum levels, it can be assumed that there is a wide variety and variability in the way which 
Mg2+ is metabolised. This would also support the idea that Mg2+ supplementation would have 
a greater effect on some participants and less on the others. There was a significant 
decrease seen in the time taken to complete the 10 kilometre running time trial. Previous 
literature also supports this finding as studies also showed the benefits of Mg2+ 
supplementation and O2 consumption at submaximal workloads (Rose, Carroll, Lowe, 
Peterson & Cooper, 1970; Brilla & Haley, 1992), total workout (Vecchiet, Pieralisi, D‟Ovidio, 
Dragani, Felzani, Mincarini, & Piovanelli, 1995) and time until exhaustion (Brilla & Gunter, 
1995). Mg2+ supplementation has also been shown to increase submaximal performance 
ultimately by decreasing submaximal VO2, VE and HR (Ripari, Pieralisi, Giamberardino & 
Vecchiet, 1989; Brilla & Gunter, 1995). Although the findings of the studies could be due to 
the fact that subjects were required to ingest higher amounts of Mg2+ or it may also be due to 
the fact that subjects already had a lower mean intake of Mg2+. Some of the studies failed to 
report the baseline Mg2+ intakes of participants. This could also be linked to the current study 
as Mg2+ intakes were high and the participants all had low dietary intakes of Mg2+. Although 
the current study utilised a highly controlled crossover experimental design, which may have 
contributed to the significant increase in performance reported. This has also been seen in 
other reports that also adopted a crossover design study and concluded significant results of 
Mg2+ supplementation (Vecchiet, Pieralisi, D‟Ovidio, Dragani, Felzani, Mincarini, & Piovanelli, 
1995). As some studies failed to assess Mg2+ status it is hard to conclude the validity of the 
reported findings, (Ripari, Pieralisi, Giamberardino & Vecchiet, 1989; Brilla and Gunter, 
1995)  as these studies failed to asses Mg2+ status prior to the supplementation intervention. 
These findings are contrasted by the reported results of studies that suggest Mg2+ will have 
no impact on exercise performance (Weight, Noakes, Labadarios, Graves, Jacobs, & 
Berman, 1988; Ruddel, Werner, & Ising, 1990; & Weller, Bachert, Meinck, Friedmann, 
Bärtsch, & Mairbäurl, 1998). Weight et al (1988) also adopted a cross over design similar to 
the current study although they found no significant effects on performance. This may be 
due to the fact that they only provided participants with 116mg/day of Mg2+ supplementation, 
which may not be an adequate amount to evoke a performance increase. The current study 
provided subjects with 500mg/day of Mg2+ supplementation and did report a significant 
increase in performance. Furthermore Weight et al (1988) recruited subjects with baseline 
Mg2+ levels of 372mg ± 122mg, which is reported to be an adequate Mg2+ daily intake. This 
may provide evidence to the theory that Mg2+ supplementation will only have a significant 
effect on performance if the individual is deficient in Mg2+, as subjects in the current study 
where below the RNI and did show significant improvements in performance after an Mg2+ 
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supplementation period, whilst the subjects partaking in Weight et al, (1988) were above the 
RNI and failed to show performance improvements.  
Even though subjects in the current study were consuming less Mg2+ than the recommend 
daily intake it cannot be concluded that they had a deficient Mg2+ status as there is still no 
simple, rapid and accurate laboratory test to determine total body Mg status in humans 
(Arnaud, 2008). However, serum Mg2+ <0.75 mmol/L is a useful measurement for deficiency 
(Arnaud, 2008). The current study did require participants to provide a venous blood sample 
so that the Mg2+ status of participants could be assessed. Average Mg2+ serum was recorded 
at 0.71 ± 0.05 mmol/L at baseline stage and increased to 0.74 ± 0.09 mmol/L post Mg2+ 
supplementation stage. Even though an increase was seen after Mg2+ supplementation the 
average serum level was still below 0.75 mmol which would suggest participants were still 
deficient in Mg2+ after five weeks of 500mg/day Mg2+ supplementation, although this may 
also support the theory that Mg2+ will only have a significant increase on performance in 
deficient subjects as significant improvements were seen in the current study and after 
acquiring and analysing blood samples and food diaries, the majority of participants appear 
to be deficient.  
10 kilometre run 
The significant decrease seen in completion times of the 10 kilometre time trials support the 
hypothesis that 500mg/day of Mg2+ supplementation will reduce the time taken to complete a 
10 kilometre run. This is demonstrated by the fact that results recorded post Mg2+ 
supplementation period were significantly faster when compared to the Mg2+ baseline stage, 
the post placebo stage and the baseline placebo stage. These findings conflict previous 
research that has been conducted into the effects of Mg2+ supplementation on running 
performance. Terblanche et al (1992) conducted a double blind placebo controlled study 
over a 10 week period. They recruited 20 experienced marathon runners and analysed the 
effects of Mg2+ supplementation on completion of a marathon, muscle damage incurred and 
the rate of recovery of muscle function following the marathon race. Terblanche et al, (1992) 
concluded that the consumption of 300-400mg2+/day supplementation for four weeks prior to 
the run had no effect on any of the variables. This confliction to the current study may be due 
to several different variables. Terblanche et al, (1992) failed to ensure that participants 
completed a marathon at baseline stage, instead they asked participants to provide their 
fastest marathon completion time which may have resulted in invalid data as the data 
provided will be subject to participant bias. Although the research protocol did require 
subjects to complete two five kilometre time trial runs, one prior to the marathon and one 
post completion of the marathon. The two five kilometre trials were conducted outside, which 
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may also affect the validity of the results as there would have been reduced control over 
external variables of the trial which could have been controlled if the run was conducted in a 
laboratory environment. 
Weight, Kathryn & Noakes (1988) also support the null hypothesis suggesting that Mg2+ will 
have no impact on sports performance. Weight, Kathryn and Noakes (1988) recruited thirty 
competitive male athletes to complete a treadmill test to exhaustion after 0, 3, 6, and 9 
months of Mg2+ supplementation. It was concluded that Mg2+ supplementation had no effect 
on performance in the treadmill trial.   
There is a lack of evidence that suggests that Mg2+ supplementation will improve the 
performance of individuals that have an established magnesium-adequate status (Nielsen & 
Lukaski, 2006). This may provide an explanation as to why Mg2+ supplementation has not 
induced performance increases in previous research. The differences in Mg2+ status may be 
the reason for the numerous conflicting reports about the effect of Mg2+ supplementation on 
exercise performance (Nielsen & Lukaski, 2006). Because many studies have failed to 
attempt to assess the Mg2+ status of participants or used insensitive methods to assess, the 
Mg2+ status of individuals before commencing with supplementation. This may have resulted 
in positive effects being seen in only the individuals that had a deficient Mg2+ status before 
the supplementation period started. 
Golf, Bohmer and Nowacki, (1993) concluded that a Mg2+ supplementation of 360mg2+/day 
when compared to a placebo supplement decreased creatine kinase levels in the blood 
serum of competitive female athletes with baseline Mg2+ concentrations at the low end of the 
range of normal values. Furthermore in a study of young men participating for seven weeks 
in a strength training programme and consuming 250mg/day of Mg2+ (most likely 
inadequate), showed a greater increase in peak knee extension torque when supplemented 
with an additional 250mg/d than those fed a placebo supplement (Brilla & Haley, 1992). 
Similar types of intakes by moderately trained adults resulted in those receiving a 
supplemental 250mg/day (instead of placebo) having improved cardiorespiratory function 
during a 30-minute submaximal exercise test (Ripari, Giamberardino, Resina & Vecchiet, 
1989). 
The current study aimed to assess the Mg2+ status of participants prior to supplementation 
through the use of food diaries and venous blood samples. This was in an attempt to 
understand the connection between Mg2+ status and the effectiveness of extra 
supplementation if Mg2+ intake is already adequate. The food diaries concluded that four of 
the participants achieved adequate Mg2+ statuses through their diets resulting in the other 
nine participants having deficient Mg2+ statuses. The sample sizes of four adequate 
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participants and nine deficient participants are too small to be a statistically valid sample. As 
nine of the thirteen participants had a deficient Mg2+ status the decrease in completion of the 
10 kilometre timed run may support the theory that Mg2+ supplementation will be effective if 
the individual is deficient. Although as the sample sizes are too small to provide validity, 
statistical analysis was not conducted on participants relevant to their Mg2+ status. So it 
cannot be concluded that the Mg2+ supplementation increased the performance of the 
deficient subjects, whilst having no effect on the participants with an adequate Mg2+ status. 
This may provide a research question as more research is needed into the effects of Mg2+ 
supplementation in relation to dietary status.          
Contrary to the above there is also literature to support the reduction in 10 kilometre run 
completion time. Previous literature has reported that Mg2+ deficiency will impair sports 
performance by increasing oxygen requirements to conduct submaximal exercise 
(Rodriguez, DiMarco & Langley; 2009). Golf et al, (1993) reported that elite male rowers with 
serum Mg2+ concentrations at the low end of the range of normal serum values used 
significantly less oxygen during a submaximal rowing ergometer test after Mg2+ 
supplementation when compared to placebo supplementation. Lukaski and Nielsen (2001) 
also support this finding as they reported that during a submaximal ergocycle, 
postmenopausal women showed reduced oxygen use, decreased heart rate and improved 
ventilatory functioning after consuming either 322 or 360Mg2+/day for a 35 day period when 
compared to 153Mg2+/day pre intervention.  
Pokan et al, (2006) further provide evidence to support the hypothesis that Mg2+ 
supplementation will have a positive impact on physical performance. Pokan et al, (2006) 
studied the effects of a six month oral Mg2+ therapy on exercise dependant heart rate as 
related to exercise tolerance and resting myocardial functioning. In a double blind controlled 
trial fifty three male participants were randomised to either oral Mg2+ or placebo 
supplementation. The six months of Mg2+ supplementation significantly increased the power 
output achieved in an incremental exercise test on a cycle   ergometer, in an upright position 
to the limit of tolerance, demonstrating that the Mg2+ therapy induced an improvement in 
aerobic power. The exercise test started at an initial workload of 20 W followed by 10 W 
increments every minute until exhaustion.   
The mechanisms responsible for the performance increases, seen due to Mg2+ 
supplementation are likely to be a result of multifactorial reasons (Shechter et al., 2000). 
Higher intracellular Mg2+ levels may improve intracellular adenosine triphosphate production 
and glucose utilisation because Mg2+ is a cofactor of adenosine triphosphate (Shechter et 
al., 2000). Mg2+ has also been reported as natures physiological calcium blocker (Iseri & 
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French, 1984; Shechter, Kaplinsky & Rabinowitz, 1992) reducing the release of calcium from 
and into the sarcoplasmic reticulum whilst protecting the cells from calcium overload under 
conditions of ischaemia. Mg2+ also reduces systemic and pulmonary vascular resistance with 
a concomitant decrease in blood pressure and a slight increase in the cardiac index (Oczek, 
Lee & Davidov, 1977; Iseri & French, 1984; Rasmussen, Larsen, meier & Larsen, 1988; 
Shechter et al, 2000). Elevation of extracellular Mg2+ levels reduces arteriolar tone and 
tension in a wide variety of arteries (Shechter,  Kaplinsky & Rabinowitz, 1996). This then 
potentiates the dilating effects of some of the endogenous vasodilators (Shechter, Kaplinsky 
& Rabinowitz, 1996). Therefore Mg2+ can result in mildly reduced systolic blood pressure, 
thereby assisting in unloading of the ischaemic ventricle (Shechter, Kaplinsky & Rabinowitz, 
1996; Whelton, & Klag, 1989; Pokan, Hofmann, Duvillard, Beaufort, Schumacher, Fruhwald, 
& Schmid, 1997; Shecter et al, 2000).  
Furthermore the improved completion time of the 10 kilometre run may be due to the Mg2+ 
vasodilation effect. Teragawa (2001) also concluded that magnesium supplementation will 
dilate both the epicardial and resistance coronary arteries. The mechanism that is potentially 
responsible for magnesium induced coronary dilation involves the activation of the 
endothelium derived nitric oxide (ENDO) pathway (Altura & Altura, 1987; Kemp, Gardiner & 
Bennett, 1993; Pearson, Evora & Secombe, 1998; Fonseca, Paiva & Silva, 1998). It is 
unclear as to whether the EDNO pathway is involved in the human coronary responses to 
magnesium. The nitric oxide (NO) pathway has numerous functions in the body, including 
the regulation of blood flow, muscle contractility, myocytes differentiation, glucose and 
calcium homeostasis, mitochondrial respiration and biogenesis (Stamler & Meissner, 2001; 
Dejam, Hunter, Schechter & Gladwin, 2004; Cooper & Giulivi, 2007).   
This finding provides further support to the alternative hypothesis concluding that Mg2+ 
supplementation will have a positive impact on aerobic exercise reducing the time taken to 
complete a 10 kilometre run. This supports the vasodilation theory as the vasodilation effect 
would allow an increased flow of blood to the muscles, increasing oxygen supply and 
muscular contraction, ultimately aiding in completion of the running time trial. 
Heaton and Elie (1983) conducted experiments using rat liver mitochondria to show that 
Mg2+ depletion in rats lead to a partial uncoupling of the respiratory chain, as evidence by a 
reduced ADP/O2
 quotient (Heaton & Elie, 1983). A disturbance in mitochondrial inner 
membrane function was responsible for this uncoupling effect. In a state of Mg2+ deficiency 
the permeability of mitochondrial membranes might increase, causing a disruption of the 
specific proton gradient required for successful ATP synthesis. Partial uncoupling of the 
respiratory chain and oxidative phosphorylation will be the result. Digiorgio et al (1962) have 
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also described similar effects, that Mg2+ deficiency will have on the mitochondrial respiratory 
chain, whilst Digiorgio et al, (1962) also described similar effects occurring in the heart 
muscle cells. If these effects of Mg2+ deficiency and its normalisation can be transferred to 
the human muscle cell, then a reduced O2 requirement should occur in the competitive 
athlete during physical stress after a period of Mg2+ supplementation. This finding brings to 
light the importance of adequate Mg2+ in the diet and could be associated with the reduction 
in completion time seen in the 10 kilometre run and other previous research that has 
reported performance improvement. 
VO2 consumption 
During the completion of the 10 kilometre run subjects were connected to a cortex metalyzer 
so that gas analysis could be conducted during the run. Results concluded there to be an 
increase in average VO2 after four weeks of consumption of 500mg/day Mg
2+. The increase 
in average VO2  was seen when post Mg
2+ was compared to the baseline Mg2+ stage, the 
post placebo stage and the pre placebo stage, although the increase recorded was not 
statistically significant. This finding would support the hypothesis that Mg2+ supplementation 
will increase VO2 consumption after four weeks of Mg
2+ supplementation. 
The reported increase in VO2 seen during the 10 kilometre run is conflicted be previous 
research that suggest Mg2+ supplementation will have no effect on VO2 consumption during 
aerobic exercise (Weight, Noakes, Labadarios, Graves,  Jacobs, & Berman, 1988; Ruddel, 
Werner & Ising, 1990;  Weight, Myburgh, & Noakes, 1988; Terblanche, Noakes, Dennis, 
Marais, & Eckert, 1992; Weller, Bachert, Meinck, Friedmann, Bärtsch, & Mairbäurl, 1998). 
Weight et al (1988) conducted a nine month placebo controlled crossover design study to 
determine whether supplementation would have a significant increase on performance of 
thirty competitive male athletes. After three months of supplementation it was concluded that 
there was no significant effect of Mg2+ supplementation. Weight et al (1988) failed to assess 
Mg2+ status prior to the completion of the supplementation period; this may explain why there 
was no significant improvement in performance as the participants may have all had an 
adequate Mg2+ status prior to the supplementation intervention period.  Ruddell et al, (1990) 
also completed a three month double blind controlled trial into the effects of Mg2+ 
supplementation on swimming performance. Ruddell et al (1990) also reported no significant 
increase in performance even when participants received 468 mg/day of Mg2+ aspartate. 
This finding may also be due to participants having an adequate Mg2+ status, although the 
studies design lacked control as the protocol failed to be of a crossover design. Weller 
(1998) also conflicts the finding of the current study as no significant improvements in 
performance were seen when participants received 500 mg/day of Mg2+ oxide for a three 
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week duration in a double blind placebo controlled study. Weller (1998) also failed to assess 
dietary status of participants prior to supplementation removing validity from the results. The 
supplementation period lasted a duration of three weeks which may not be enough time for 
adaptation to have an effect, hence why no significant improvements in performance were 
recorded. 
This increase in average VO2 seen after the Mg
2+ intervention period has been reported 
before by previous literature that has found a relationship between plasma magnesium and 
maximal oxygen consumption in trained athletes (Lukaski, Bolonchuk, Klevay, Milne & 
Standstead, 1983). Lukaski et al (1983) took forty-four healthy male university athletes and 
twenty untrained men and put them through maximal treadmill exercise testing aiming to 
determine the relationship between maximal oxygen consumption and Mg2+ status. Lukaski 
et al (1983) concluded that average maximal oxygen consumption was significantly higher 
post supplementation period and that plasma Mg2+ was significantly correlated with oxygen 
consumption. This may suggest the possibility of a metabolic role for Mg2+ during a state of 
strenuous exercise other than its already acknowledged role as a co-factor to over 325 
enzymatic reactions and in neuromuscular functions (Wacker & Parisi, 1968; Shils, 1980; 
Newhouse & Finstad, 2000).  
Blood Pressure 
The current study also aimed to research the hypothesis suggesting that Mg2+ 
supplementation will have a significant effect on blood pressure. Blood pressure readings 
were recorded during the clinical trial both before and after the 10 kilometre run. Previous 
research has both supported (Dyckner & Wester, 1983; Sanjuliani, Fagundes & 
Francischetti, 1996; Kawasaki, Itoh, & Kawasaki, 1998; Kawano et al 1998; Sacks et al, 
1998; Hatzistavri, Sarafidis, Georgianos, Tziolas, Aroditis, Zebekakis, & Lasaridis, 2009) and 
conflicted (Cappuccio, Markandu, Beynon, Shore, Sampson, & MacGregor, 1985; Patki, 
Singh, Gokhale, Bulakh, Shrotri, & Patwardhan, 1990; Zemel, Zemel, Urberg, Douglas, 
Geiser, & Sowers, 1990; Ferrara, Iannuzzi, Castaldo, Iannuzzi, Russo, & Mancini, 1992) the 
effects that Mg2+ supplementation has on blood pressure.  
Hatzistavri et al, (2009) concluded that Mg2+ supplementation has a significant impact on 
reducing blood pressure, which supports the findings of the current study that also found a 
significant reduction in blood pressure after a five week Mg2+ supplementation period. The 
significant decrease in diastolic blood pressure was recorded both before and after to the 10 
kilometre running trial whereas the significant decrease seen in the systolic blood pressure 
was only seen following the run. As a result of this conclusion the alternative hypothesis may 
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be accepted suggesting that Mg2+ supplementation will invoke a significant decrease in blood 
pressure.  
Zemel et al, (1990) conducted a clinical trial into the effects of Mg2+ supplementation on 
blood pressure, thirteen patients with mild hypertension were analysed for a three month 
period seven of which were supplemented with 40 mmol of Mg2+ asparate whilst the 
remainder were supplemented with placebo. It was concluded after the supplementation 
period there was no significant decrease seen in blood pressure. Ferrara (1992) further 
supported this finding after conducting a double-blind parallel clinical trial for a period of six 
months. Fourteen mild to moderate hypertensives‟ were randomly given either Mg2+ or 
placebo supplementation. These studies may have failed to find positive results due to their 
methods lacking a crossover design. It has also been suggested that Mg2+ supplementation 
will only affect blood pressure if the individual is deficient in Mg2+. As it is difficult to assess 
Mg2+ status and the studies failed to attempt this in their methods, it may be suggested that 
this variable may be responsible for a lack of reduction seen in blood pressure.  
A meta-analysis conducted by Kass, Weekes and Carpenter (2012) conflicts the research 
that suggests Mg2+ supplementation will have no impact on blood pressure. Kass et al, 
(2012) conducted a meta-analysis to assess the effect of Mg2+ supplementation on blood 
pressure. The analysis included 22 different trials with a supplemented elemental Mg2+ range 
of 120-973mg. After statistical analysis was conducted it was concluded that Mg2+ 
supplementation had a dose dependant effect on blood pressure. Studies that provided 
subjects with >370mg/day Mg2+ recorded greater reductions in blood pressure.   
Hatzistavri et al, (2009) studied the association between blood pressure levels and serum 
Mg2+ analysing if there was a correlation between the levels of Mg2+ found in blood serum 
and a change in the blood pressure readings. They took measurements of intracellular Ca2+ 
and Mg2+ alongside the blood pressure via blood samples collected in a vein catheter. 
It was concluded after correlation analysis that there was a weak-to-moderate non-significant 
association between the changes in blood pressure and the changes in the serum 
intracellular ion levels in the intervention group, which would suggest that the relationship 
between Mg2+ serum levels and blood pressure needs to be researched in greater depth.  As 
the current study also required subjects to provide a venous blood sample, correlation 
analysis could be conducted to provide further assessment into the relationship between 
serum Mg2+ and blood pressure. Correlation analysis revealed a significant, moderate 
negative correlation between blood pressure and serum Mg2+ (r = -0.5). This also supports 
the idea that there may be a connection between the two variables, because as Mg2+ serum 
levels increase within the blood, blood pressure levels appear to drop accordingly. As the 
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correlation between the two variables is only moderate further research is required to 
establish if there is a definitive connection between serum Mg2+ status and blood pressure, 
although this finding is supported by previous literature and supports the findings of the 
current trial (Hatzistavri, Sarafidis, Georgianos, Tziolas, Aroditis, Zebekakis, & Lasaridis, 
2009).  
Despite the clinical and experimental research on the field, several aspects concerning the 
exact mechanisms through witch Mg2+ exerts its BP-lowering effects still remain unclear 
(Hatzistavri, Sarafidis, Georgianos, Tziolas, Aroditis, Zebekakis, & Lasaridis, 2009). Among 
the several different mechanism proposed, a pivotal role could be due to the impact of Mg2+ 
on vascular smooth muscle cell tone, reactivity and contractility (Laurant, & Touyz, 2000; 
Touyz, 2003; Barbagallo, Dominguez, Galioto, Cani, Malfa, & Paolisso, 2003). Inside the 
vascular smooth muscle cells, Mg2+ is said to act extracellulary by inhibiting transmembrane 
Ca2+ transport and Ca2+ entry, or acting intracellularlarly as a Ca2+ antagonist, thereby 
modulating the vasoconstriction action of increased intracellular Ca2+ (Touyz, 2003; 
Mubagwa, Gwanyanya, Zakharov, & Macianskiene, 2007). Furthermore, the influence of 
Mg2+ on vascular tone and reactivity could also be mediated by its role on the Na/K ATPase 
activity, which regulates the transmembrane Na+ and K+ transport (Touyz 2003; Barbagallo, 
Dominguez, Galioto, Cani, Malfa, & Paolisso, 2003; Mubagwa, Gwanyanya, Zakharov, & 
Macianskiene, 2007). 
Mg2+ has been said to play an important role in the regulation of various cation channels in 
the cardiovascular system. (Mubagwa, Gwanyanya, Zakharov, & Macianskiene, 2007) The 
proposed mechanics underlying the effect of Mg2+ involve either a direct interaction with the 
channel, or an indirect modification of channel functioning via various proteins, such as 
enzymes and G proteins, which have been reported to covalently modify or interact with the 
channel (Mubagwa, Gwanyanya, Zakharov, & Macianskiene, 2007). 
The theory that Mg2+ plays a vital role in the regulation of Na/K ATPase activity is supported 
by previous research (Fischer & Giroux, 1987). Fischer & Giroux (1987) fed Dawley rats a 
basal diet containing 200, 350, 500, or 650mg of Mg2+ per kilogram of bodyweight for a 
duration of 6 weeks. Fischer & Giroux reported ATPase activity to increase with increasing 
dietary intake, so the rats that were fed 500mg and 650mg of Mg2+/Kg had significantly 
greater ATPase activity than those that were fed the diets containing 80mg and 200mg of 
Mg2+/Kg.  
This data provides direct evidence that Mg2+ deficiency decreases the activity of the sodium 
potassium pump in cardiac tissue (Fischer & Giroux, 1987). Although as the Fischer and 
Giroux (1987) study was conducted on animals it cannot be assumed the same results will 
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occur in humans. The current study may also provide further support to the theory that Mg2+ 
deficiency reduces the activity of the sodium potassium pump.    
A state of Mg2+ deficiency may lead to abnormal functioning of the Na+/K+-ATPase pump, 
resulting in an abnormally low plasma potassium concentration. A state of abnormally low 
plasma is more commonly referred to as hypokalemia, which is most commonly caused by 
the use of some diuretics, some forms of kidney disease, or metabolic disturbances. These 
symptoms have been related to alterations in membrane potential and cellular metabolism, 
including fatigue, muscle weakness and cramps, which would ultimately lead to a reduction 
in sports performance (Sheng, 2000).     
The current study shows that Mg2+ supplementation will have a lowering effect on diastolic 
blood pressure and systolic blood pressure, although as there is confliction within the 
literature further analysis is needed for Mg2+ supplementations effect on blood pressure to be 
conclusive. 
Heart Rate  
During completion of the 10 kilometre run, participant‟s heart rate was recorded in 10 minute 
intervals. After completion of the study it was concluded that there was a significant variation 
in heart rate when the post Mg2+ results where compared to the post placebo results. 
Therefore the alternative hypothesis can be accepted, as Mg2+ supplementation appears to 
have a significant impact on heart rate.  
Few previous clinical trials have analysed the effects that oral Mg2+ supplementation has on 
heart rate/myocardial functioning. The current study concluded there to be a significant 
variation in heart rate after completion of the Mg2+ supplementation period. This may provide 
evidence of an increased level of performance as there was a significant decrease in time 
taken to complete the 10 kilometre running trial. Participants of the study completed the 10 
kilometre run significantly faster after the Mg2+ supplementation period. This increase in 
performance would have resulted in increased physical exertion, suggestively leading to an 
increased average heart rate. The significant decrease seen in average heart rate after the 
Mg2+ supplementation period may show an increased efficiency of the heart, resulting in 
participants being able to increase physical exertion, whilst the heart rate is reduced 
significantly.  
Pokan et al, (2006) concluded there to be a reduction in heart rate during a maximal 
exercise test after an Mg2+ supplementation intervention. The investigators also concluded 
there to be a significant alteration in heart rate response in the Mg2+ group after the 
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intervention, with no change recorded in the placebo group. Finally  Poken et al, (2006) also 
conducted an echocardiography on subjects and a significant change was seen in left 
ventricular end systolic diameter (LVSD) after the Mg2+ intervention period. The left 
ventricular, end systolic diameter reduced from 36.1 ± 0.5 before intervention to 31.5 ± 0.4 
following the intervention period. These findings may provide a rational as to why there was 
no significant increase in heart rate related to the significant decrease in completion time of 
the 10 kilometre run.  
All participants that took part in the Poken et al, (2006) clinical trial had a deficient Mg2+ 
status at baseline observation. This may be responsible for the significant differences 
recorded after 6 months of oral Mg2+ supplementation. Again this increase in Mg2+ status 
may have also improved intracellular adenosine triphosphate production and glucose 
utilisation due to the fact that Mg2+ is a co-factor of adenosine triphosphate (Shechter, Paul-
Labrador & Rabinowitz, 1998),ultimately resulting in an increase in performance.   
Although these findings support the alternative hypothesis suggesting Mg2+ supplementation 
will have a positive effect on heart rate/myocardial functioning, a clinical trial conducted by 
Dyckner & Wester (1983) provides confliction. Dyckner and Wester (1983) also conducted 
analysis into the effects of Mg2+ supplementation on heart rate, after a six month Mg2+ 
intervention period, during which subjects were supplemented with 15 mmol/day of Mg2+ 
aspartate. Following the six month intervention period it was concluded that there was no 
significant difference in heart rate (Dyckner & Wester, 1983). Dyckner & Wester (1983) failed 
to assess the Mg2+ status of participants prior to the intervention period. This may be a 
limitation to the clinical trial, as it may have been that the participants had a deficient Mg2+ 
status prior to conduction of the study, resulting in no benefit from further Mg2+ 
supplementation. This may be why Dyckner and Wester (1983) recorded no positive effects 
from the Mg2+ intervention.  
Blood Serum 
Assessing Mg2+ status accurately is difficult as clinical tests of Mg2+ status are still lacking, 
therefore it is hard to diagnose magnesium deficiency (Jahnen-Dechent & Ketteler, 2012). 
Evaluation of serum Mg2+ concentration and collection of urine samples are the most 
accurate assessments available at this present time, for the diagnosis of Mg2+ deficiency. 
Approximately 1% of the total body magnesium is present in the serum and intestinal bodily 
fluids (Elin, 1987). The mean serum magnesium concentration in humans is roughly 0.85 
mmol/L, with a referenced interval of 0.7-1.mmol/L (Wacker, 1980). In serum, approximately 
one third of Mg2+ is bound to protein, 25% is bound to albumin and 8% to globulins (Kroll & 
Elin, 1985). For the two thirds of the plasma Mg2+ that is ultrafiltrable, approximately 80% is 
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in the form of free ion and approximately 20% is complexed to phosphate, citrate and other 
compounds (Walser, 1967). The current study aimed to test the hypothesis that Mg2+ 
supplementation will have a significant increase on Mg2+ serum levels following a four week 
intervention period. Previous research into the effects of Mg2+ on blood serum levels is 
contradictive, with some studies supporting (Cappuccio, Markandu, Beynon, Shore, 
Sampson & MacGregor, 1985; Itoh, Kawasaki & Nakamura, 1997; Hatzistavri et al, 2009) 
whist other studies (Zemel et al, 1990; Geleijnse et al, 1994; Wirell et al, 1994 & Witteman et 
al, 1994) reject the idea that Mg2+ levels in the serum could be affected by Mg2+ 
supplementation. The current study also required participants to complete a four day food 
diary, to assess Mg2+ status prior to the Mg2+ intervention period. Although several studies 
have suggested that dietary Mg2+ will not correlate with serum magnesium levels because 
renal Mg2+ handling affects total body serum Mg2+ more than dietary consumption of Mg2+ 
(Chakraborti, Chakraborti, Mandal, Mandal, Das & Ghosh, 2002).  
Itoh, Kawasaki & Nakamura, (1997) contradict this idea as the results of a double blind 
placebo controlled study indicated that, in middle aged subjects of both sexes, oral Mg2+ 
supplementation for a period of four weeks can produce significant increases in serum levels 
of Mg2+. The significant increase recorded was seen in subjects that had an adequate 
baseline level of Mg2+ (0.85 mmol/l) and were consuming adequate intakes of Mg2+ through 
their diets (225 mkg/d). These findings conflict the findings of the current study, although the 
daily Mg2+ dosage was higher, (548mg Mg/d) which may have been related to the significant 
increases seen in Mg2+ serum levels.  
Hatzistavri et al (2009) also provided subjects with high dosages of Mg2+ supplementation 
(600mg mg/day), throughout the clinical trial. Hatzistavri et al (2009) also concluded there to 
be a significant increase in serum level Mg2+ after a twelve week supplementation period. 
This confliction to the current clinical trial may be due to the higher Mg2+ supplementation or 
longer duration of the supplementation intervention as the current trial only required 500mg 
Mg2+/day for a four week duration.  
As no significant difference in Mg2+ serum level was recorded in the current trial the null 
hypothesis was accepted suggesting that Mg2+ supplementation had no effect on serum 
levels of Mg2+. This is contradictory, as trials that have reported a significant decrease in 
blood pressure, usually also report a significant increase in Mg2+ serum levels (Itoh, 
Kawasaki & Nakamura, 1997; Hatzistavri et al, 2009). The lack of significant increase in 
Mg2+ serum levels seen in the current study may be due to the body storing the 
supplemented Mg2+ in bone or muscle storage, as blood serum is known to contain only 1% 
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of total body Mg2+ (Elin, 1987) and participants showed signs of deficiency with baseline 
serum levels and food diaries, showing Mg2+ intakes of less than 300mg Mg2+/day. 
Power     
A bench press till fatigue trial was conducted both pre and post the 10 kilometre run. 
Participants were required to bench press (until fatigue) 75% of their ORM followed directly 
by 50% of their ORM. During the trial both peak and average power was recoded, the aim of 
the present study was to investigate whether an Mg2+ supplementation period would 
significantly increase average power in a bench press trial to fatigue.  
The current study concluded there to be no significant difference in peak power or average 
power at 75% and 50% of ORM both pre and post the 10 kilometre run. Therefore the null 
hypothesis will be accepted due to a lack of significant change. It is important to note that 
whilst there is research that reports Mg2+ supplementation to have no effect on exercise 
performance there is still no research reporting negative effects of Mg2+ supplementation 
(Newhouse & Finstaad, 2000).  
Previous literature that has investigated the effects of Mg2+ supplementation on power 
performance both support (Ripari, Pieralisi, Giamberardino, Resina & Vecchiet, 1989; Brilla 
& Haley, 1992; Brilla & Gunter, 1995; Golf, Bender & Gruttner, 1998) and conflict (Weight, 
Myburgh & Noakes, 1988; Terblanche, Noakes, Dennis, Marais & Eckert, 1992; Ruddel, 
Werner & Ising, 1990; Weller, Bachert, Meinck, Friedmann, Bartsch & Mairbaurl, 1998) its 
impact, so whether Mg2+ supplementation improves muscle functioning still remains to be 
shown (Dominguez, Barbagallo, Lauretani, Bandinelli, Bos, Corsi, Simonsick & Ferrucci, 
2006). 
Dominguez et al, (2006) support the hypothesis that Mg2+ supplementation will have a 
positive impact on sports performance, they sampled 1138 men and women ages 66.7 ± 
15.2 years who were not severely cognitively compromised and had no evidence of kidney 
disease or hypercalcemia. Muscle performance was evaluated by grip strength, lower leg 
muscle power, knee extension torque and ankle extension isometric strength. Dominguez et 
al, (2006) found a significant, independent and strong relation between circulating Mg2+ and 
muscle performance which was consistent across several muscle variables in both men and 
women. Dominguez et al, (2006) didn‟t provide subjects with Mg2+ supplementation, but 
assessed Mg2+ status and compared that to muscular performance in the older persons. This 
provides a study limitation as it cannot be concluded that the positive correlation seen 
between Mg2+ status and strength performance is solely caused by the Mg2+ level as there 
may be several other variables affecting this increase in muscular performance.  
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Brilla and Haley (1992) investigated the effects of dietary Mg2+ on strength development 
during a double blind 7 week strength training program in twenty six untrained subjects (14 = 
control and 12 = Mg2+ supplemented) between 18-30 years of age. Brilla and Haley provided 
supplementation of 8mg/kg of body weight/day. Strength was assessed with each subject 
performing three sets of ten repetitions, leg press and leg extension, three times a week. 
Brilla and Haley reported that both groups gained strength, however results reported a 
significant increase in strength for the Mg2+ group when compared to the control group in 
absolute and relative torque adjusted for body weight. This finding provides further support 
to the hypothesis that Mg2+ supplementation will improve strength. Brilla and Haley (1992) 
also conducted dietary assessments over a three day period to assure that subjects were 
adequate in Mg2+ status. The current study did not require participants to conduct maximal 
strength exertion, just exertion of strength till fatigue, which may be the limitation which 
resulted in no significant differences occurring.  
Brilla, Giroux, Taylor & Knutzen (2003) followed up on the previous study (Brilla & Haley, 
1992) by evaluating the effect of Mg2+-creatine supplementation on body water and 
quadriceps torque. Participants were required to consume supplementation consisting of 
800mg Mg2+/day and 5g of creatine daily for a period of two weeks in a random assignment 
clinical trial. Brilla et al, (2003) concluded there to be a significant increase in quadriceps 
muscle torque when the Mg2+-Creatine group was compared to the placebo intervention 
group. Although this study provides further evidence for the hypothesis that Mg2+ 
supplementation will have a significant increase on performance it cannot be determined 
whether performances increments were due to the 800mg of Mg2+, the 5g of creatine or a 
combination of the two. This conflicts the finding of the current clinical trial which may also 
be due to the design limitation as participants were required to exercise to fatigue rather than 
a maximal output.  
There are three potential mechanisms that may explain the performance improvements 
recorded in the previous clinical trials These are the role of Mg2+ in energetic metabolism, 
the increased relative oxygen species production in a state of Mg2+ deficiency and the 
proinflammatory effect of Mg2+ depletion. The previous studies discussed that were 
conducted on young participants, reported a significant increase in muscle performance, 
which may be due to Mg2+ key role in energetic metabolism, trans membrane transport, and 
muscle contraction and relaxation (Lukaski, 2004). A deficient Mg2+ status has been linked to 
structural damage to muscle cells through increased oxidative stress and impaired 
intracellular calcium homeostasis (Rock, Astier, Vignon, Gueux, Motta & Rayssiguier, 1995). 
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The majority of energy used in physiological functions in humans is produced in the 
mitochondria via the movement of electrons through the respiratory chain (Short, Bigelow, 
Kahl, Singh, Coenen-Schimke, Raghavakaimal, Nair, 2005). Mg2+ is known to be critical for 
basic mitochondrial functions, including ATP synthesis, electron transport chain complex 
subunits, and oxygen detoxification (Wolf & Cittadini, 2003). A deficient Mg2+ status may lead 
to a reduction in mitochondrial efficiency and increased production of relative oxygen 
species with consequent structural and functional impairment to proteins (Liu, Head, Gharib, 
Yuan, Ingersoll, Hagen, & Ames, 2002), DNA (Short, Bigelow, Kahl, Singh, Coenen-
Schimke, Raghavakaimal, Nair, 2005), and other essential molecules, ultimately preventing 
strength gains and power improvements.  
The level of Mg2+ present in the mitochondria can represent up to one third of total body 
Mg2+ and is present as a complex with ATP and as a component of membranes and nucleic 
acids (Wolf & Cittadini, 2003). Studies into the effects of Mg2+ deficiency in humans and 
animals has reported evidence of decreased antioxidant capacity (Dickens, Weglicki, & Mak, 
1992; Freedman, Mak, Stafford, Dickens, Cassidy, Muesing, & Weglicki, 1992), with studies 
concluding a link between Mg2+ deficiency, mitochondrial swelling and altered ultra-structure 
in animal muscle (Rock, Astier, Vignon, Gueux, Motta & Rayssiguier, 1995), providing further 
explanation to the link between power and Mg2+ status. 
Newhouse and Finstad (2000) conducted a meta-analysis into the effects of Mg2+ 
supplementation on sports performance. Out of twelve different studies analysed it was 
concluded that Mg2+ supplementation would have no increase in sports performance or 
power, with only three studies showing strength-related dependant variables. With only three 
studies to draw upon further research is needed to conclude the effects of Mg2+ 
supplementation on power. One consistency between pervious research is that 
improvements are seen in participants that have a lower state of fitness. The majority of 
previous research that reports a lack of effect has used highly trained athletes as subjects. 
Therefore supporting the theory that Mg2+ supplementation will be able to address a weak 
link in the physiology of untrained subjects whilst training has somehow strengthened this 
weak leak, although more research is needed to expand on this observation (Newhouse & 
Finstad, 2000).  
This may provide a rational as to why in the current study Mg2+ supplementation failed to 
produce a significant increase in peak and average power, as all participants needed to be 
recreationally active and fit enough to ensure completion of a 10 kilometre run. The lack of 
results could also be linked to the study design, which required subjects to complete the trial 
to fatigue rather than maximal exertion. 
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Limitations  
This study aimed to be the first to assess participants Mg2+ status through the use of food 
diaries and blood samples and relate that status to performance. After analysis of the food 
diaries it was concluded that there was only three subjects with an adequate Mg2+ status. A 
sample size of four was not enough to provide a significant comparison. This provides 
limitation to the current study as it would have proved to be more effective to screen the 
participants for their Mg2+ status prior to the conduction of the protocol. This way subjects 
could have been excluded or included to the protocol depending on Mg2+ status, resulting in 
equal groups for comparison. Participants were not screened for Mg2+ status prior to the 
completion of the study due to time restraints placed on the research project. It would have 
been a time consuming process to create two groups based on Mg2+ status as the majority 
of individuals are deficient in Mg2+, leaving less individuals with an adequate Mg2+ status. 
Although this does provide a topic for new research as greater depth is needed into the 
effects of Mg2+ supplementation in relation to Mg2+ status.  
Mg2+ supplementation presented to participants may also have proved to be a limitation, 
resulting in a lack of significant results. Previous studies have reported significant effects 
from Mg2+ supplementation of 800mg/day (Brilla, Giroux, Taylor & Knutzen 2003). The 
current study only required participants to consume 500mg/day of Mg2+ supplementation 
which may have resulted in some insignificant results, although previous literature has 
suggested that ingestion of 500mg/day of Mg2+ can result in gastrointestinal disturbances, 
particularly diarrhoea in some individuals, and often may exert a negative effect on 
phosphate balance (Lukaski, 1995). In future research an extra group could be added 
alongside the current groups, containing a higher dosage of Mg2+.  
The bench press till fatigue trial also contained limitations that may have affected the results 
of the study. The bench press trial required participants to complete as many repetitions as 
possible of their ORM until failure. If the study had required participants to exert as much 
force as possible (maximal) rather than until fatigue, there may have been an increase seen 
in the power readings recorded.     
The participant sample size may also provide limitation to the current clinical. The final 
sample size for the clinical trial was 13 participants. Although this amount was seen as 
significant after a power analysis to provide validity a larger sample size would have 
provided an increased level of validity, furthermore the majority of subjects were male with 
only four participants being female. This is due to opportunity sampling, with many females 
not willing to partake in the study. This dominant male sample group may remove some 
validity from the trial and the effects of Mg2+ supplementation on the female population. 
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Cultural bias was also another limitation of the clinical trial as subjects recruited were all from 
a similar cultural background, again due to the opportunity sample. This will mean that the 
current findings cannot be generalised to all cultures.  
Supplementation length may have also provided limitation to the current clinical trial, as 
previous research has contained supplementation periods of up to six months. The current 
study contained a five week supplementation period which may have not been long enough 
to affect Mg2+ status significantly. Although as the current clinical trial was of a crossover 
design and contained a washout period, of five weeks, an extension of supplementation 
period would have dramatically increased the studies duration. This may provide the 
rationale for a research project that assesses the optional length for supplementation.  
Conclusion  
In conclusion the results of the current study show that 500mg/day of Mg2+ supplementation 
will significantly decrease time taken to complete a 10 kilometre run, reduce systolic and 
diastolic blood pressure and significantly reduce HR. As Mg2+ is a co-factor in over 325 
enzymatic reactions (Newhouse & Finstad, 2000), it‟s importance as a mineral is clear and 
warrants research to improve scientific knowledge into its role within health and sports 
performance, as Mg2+ deficiency can also be detrimental to health. 
Taking into consideration the findings of the current study, the positive results recorded 
suggest that Mg2+ supplementation will be beneficial for sports performance and certain 
health aspects. Therefore it can be concluded that it is worth taking Mg2+ supplementation to 
aid with health and performance. The current study provides conclusive evidence into the 
benefits of Mg2+ although if the study was to be conducted again, more attention would be 
paid to participant‟s baseline Mg2+ status to provide a conclusion to the question: does Mg2+ 
supplementation provide further benefit to individuals that achieve optimal Mg2+ status 
through their diets?  
Future Research 
 One future research questions can be drawn from the current clinical trial, which is as 
follows: Does Mg2+ supplementation improve performance in individuals with adequate 
dietary intake vs individuals with a deficient dietary intake?  This further research would 
provide a greater depth of knowledge and may help to improve the understanding of how 
deficiency in Mg2+ can be detrimental to health and how Mg2+ supplementation can be 
beneficial to health and sports performance.  
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